September 1995 PSYCHIATRIC LRWCE S A Journal American of the Psychiatric Association Formerly Community A National the Study of Effectiveness of Mobile Crisis A New Mental Colunm Health on Care in the States ‘Reform Command and f the of Hallucinations Likelihood Dangerous Hospital Behavior Readmission Female With Services Veterans Substance Abuse Hospital Psychiatryand HALDOL#{174} Decanoate (HALOPERIDOL) Offer INJECTION your 100 100 mg/mL patients the most consistent relapse protection 4 Establish a safe, effective How Much? How Often? How Patients who are Stabilized Ofl oral doses :S1O mg/day, who are elderly, or who are debilitated2 Patients who are maintained on oral doses >10 mg/day, who are tolerant to oral medication, or who are at risk for relaps& Initial month’s dose is 10 to 15 times patient’s daily oral dose*2 Initial month’s daily oral dose*2 100 mg, the balance of the first month’s dosage can be administered Total monthly dose should not exceed 450 mg #{149} Maximum volume per injection site should not exceed U *Supplementation 10 to 15 times daily oral dose depending with oral haloperidol Decanoate 3 to 7 days later For is a brisi mnwy only. k$ors isc#{241}bk,s Decanoate 3 mL on clinical response2 can be used during periods ofdose 50 I HALDOL (hr$dol) 1IsiM should not exceed dose is 20 times patient’s U Maintenance 0 T dose #{149} Once a month #{149} Since the first injection High? HALDOL oral haloperidol adjustments I 00 (hr$doI) $con cempe uc Mdonnatlon 10 to 15 times daily oral dose depending on clinical response2 #{149} 1120 times the daily oral dose is used, monthly dose should be reduced based on clinical response (by approximately 25% of the original dose, each month for 2 months) until appropriate maintenance dose is reached3 U HALOOLai HALDOLDecaloats ONTRAIOOICAT1OItSrnce me pharmacog and chnc abo of KALDOIDecanoate50 and HALDOIDecanoate 1 are attnbuted to HALDOIhaIopend the activemethcatmn,CONTRAINICATIONS, WARNINGS.ai addmon intomiahon are those ot HALDOLmodthed to reflect the pronged actn. HALDOLo cOdTarnd in severe toot centr nervous syslero depression or comatose states from any causear in ndrviduas whoare hypersensitrto ho drug or have Parlonson’sdsee. WARNINGS:TaithoS D#{216}ioaia: Jordandonesa a syndrome constrr potent rreverob, nvuntary, dysnet mments may develop in patents treatt ecth aobpsyctiohc drugs though the preva’enceof the syndrome appears to hhest among the eldenty, ciaOyetdey women, 6 imposob to ry upon prevalenceOnt to predict, at the ncepon ofaobps#{216}otic treatment w$rfl patients are Iy to devop the syridronre.ether aopsychoc dregprodocis ddter in then pOter to canoe tardne dysnema unknown. Boththe osk of developrngtarthve dyskoresiaand the bkehhoodthat d willbecome irrevemibe are heaved to increase as the durahon oftreatment and the totd cumuhve dose of aotc dnigs minndered tothe patientincrease. Hover, the syndronrecan devetop,although much ss commordy, after rendy heel treatment s at w doses There no known treatment for eStahnd cases of tarthve dndones although fe syndrome may remit. itiaI$y or compteteIy d anhpsychnd treatment rewithdrawn.Mtipsychotic treatment dselt. may suppress (or suppress)ttre sqns and symptoms ofthe syndrome aid thereby may possy mask the undedym9 process The effect that syrnptomatc suppremaon h upon the ngterm course of the syndmme o unknown. Gn these condemhons, aItS#{216}OtE dni shotddbe prrecrthedma mannerthato most liheyfo minimoe the occurrence ofhede dyskinesia Ghron acthpshohctreaheeN shou generaty be reservrelfor pahen who suttenfrom athron knessth 1)6 kflOWflto reSPOfldtoaflhpSyChOhC drugs, and 2)torwhorn afterrre tree. equaty eflechve,but potentiy ss twmtUt treatments are m avadabe orappropdate. In paben who do reqtarechrorec treatment the snndst dose and the shortest durahon oftreatment producanffa satretactorydrec response shoidd he sotht the ne for coetmued heat mendshcoid he reassessed eiy Uogro and synmoma oftarthve dysnesiaappear ina pabenton aohpsychohcs, drug docOchnUahOn shoo be considered. Hover, snare patients may require treatment despde the presence ofthe syndmme. (For further informahonaboot the descnphenof tardan dysnesiaaod dsdini detechon, ease referto ADVERSEREACTIONS.) NsurIc Mat $omo (N A pOtentiaffytahe symptom compeo somehmre referred to as NeUrOIept Mahgnant Syndreme )NMS)h been reportedin socndme ndthanhpsychOtc dnigs. Ghroc mandeshoem of NMSare hyperpyrer moscN rfly, ahernd men he status(inctuthr catatomc ogns)and credenceof aotonomc ffistady)wrear puheor Nood pressure tachycarth dhoresre, and car dysihythnnian).AddthonndS19fl5may irctu elevatedcreabre phospholanase, myngtobnur)thabdomyos)and arote mindtadure. The thagnosoc evahiation ofpatents with ho syndrome comnd. InarrMng at a thagnosis, 0 mpornt to enhty cases where the chnc presernahon endudes both sermon mnd ilness)e g, pneumona syntem intechon,etc)aod untreatrelorinadequaheyheated ectmpyrami d ogns and symptoms )EPS).Other impornantconoderahons n the dd?erentnddnoso indude centr anhchohnergEtmdc4 heat stroke, dreg feverand pnnwy centok nervota system CR5) pathstogy. The maroement of NMS thou endude 1) immedst dkeoohnuahoo of anbpsychotc dnigs and other dregs nst essentnd to concUrrentthery, 2) intensivesymptomabc treatment and methcst mondoflng, and 3)treatmerd ofanyconcomdant sedous medist proNemsforwhch specAc treatmenareavadabi Thereo nogenerst memerdakostsn cthcpharmacotrcst treatment reimeos for uncnmphcatedNMS.Ua paherd reqUiresanhpsychohc drug treatment after recoveryfrom NMS, the potentndrnntroduchon of dreg therapy shoust hecarefUffycOnSideOndThepaherdshootr hecaretoky mondorod,some recorrencroofNMS have keen reported. Iypeipyremaand heat stroke. rotsociated wok theabove symptom complex,haveatso keen reported wok HAIDOL Deep a Pmiaucy)sec PRECAUTIONS - Usage in Pregnancy) C.m Uoa WOhLiDeoec)sec PRECAUTiONS-Drug Interachons) Geooral: Bronchopneumon sometimes fahe, has f000weduse of anhpsychotc drags, indudieg hstopendoi Prorn rennedndtherapy shostd he instdotnd d dehydration, hemoconcentrahon or reduced polmonary venthhon occor, ropecahy in the estedy. Dweasrel senim chOinsteist and/or cotanecaa and ocular changes have been reponikewith themca1yrekend drags, although nOioath tnlopendo&See PRECAU1ONS IntormahontonPahentotor intormahonon mend and/or phyncOiOiahbesandon concomdant osewdh othersobstances. PRECAUTIONS:Mminrster casteously to paben 1) oath severe carthovascotar doorders, due to ftre possMy of tranreent hy$ensoto aOd/O1prepdahon ofangonotpnn)d avanopressor o regarred,nsphnnsshouki not he nnd once HALDOLmay OiockHsvasopressorxtrv ny and paradootcotfurther tawenng of strandpressure may OcCUTmetararmnol,phenytephnneor norepmeph#{241}ne shoost he Used): 2) receng anhconvukanf medcations, oath a hndoryof seoures or wdh EEGabnomnatthes,because HALDOImay tewer the sononteob threshote. HinOi caSed,adequateanbconvutsatflthery shouki be concomHAnfly mOinkened.)3)wdfr knownaIIerg ora historyat aterg reachons to drags; )4) receiving anticoagulaots, since an isolated instance of interference occurred ndththe effects of one anticoagulant )pheoindione). Concomdantanhgsdonsonmedcahon,d reqoired may hare to hecontanoed after HALDOLo doconbnued becaUseot&fferentencrebon rates; d both are doconhnued omuffaneousty,extrapyranndotsymptoms may occur.Intraocoterpressure may recrease when anhthohnerg drog inchotinganfrgsrtrnson drugs, are admiotetenedconcomoanhy wdh HALDOLWhen HALDOLo used ton montein tapotar dteorders there may be a rapot mood ong to depresroon. Severe neorotoobdy may occur in pabento wok thyrotooicosrorecnvir anhpsychokc medtrahon, vekotmg HALDOL. WaoaaOoa Nt PatWat Menhe and/or phyncot abdthes requirndton hazardoirolarks or dnvmg may be impaned. Aicohotshou he avoided dueto posrabtealdthve efIectSarOihypotenoon 0mg etoraOiIoo Potnte recenang lithomptrs hatependot shoont he morotored ctasotyfor andy eradenceof neurOiogOi toxctty and treOi meit doconbnoed promphyd such ragosappear As ante otheranhpsychohc agents. Cshoute be noted that HALDOLmay he capatre ofpotenRahegONSdePreSSantSSIJchananesthetea, oprat andalcohot caroMoii agsosais W iploasat of FesIIII No mutenc potenhal of halopendolwan found n the Ames SalmoneOanalcnosonok achvaflonassay. Negaton or inconrastentposthve Indrogs have been obtamed in ro vntroaod ro v studes of effects of halopendoton chromosome structure and numher The available cytogenetic evidence is considered too inconsistent to be conclosive at this frme. Carnogencity otodmousreg oral hato were cOndUCtndm Wotar rats )dooedot op to 5 nngOcgdoty for 24 montho)and mAlbinoSwtes nace)dosedatupto5mgthgdadyhe l8months). InffrertestudysumeOiwankesthanophmalinaOdosegmu redtegftrenumherof ratsat nob tondevelopoegtUmors.HoOnver,althougha retahvetygreoter nUmberof rats survoed to the oral ofthe study inh#{231}h dose male nd temah groups these enmals dot not have a greatenincotenceofturnors than controt anmials. Therefore,Oithn4 npknnaEthi shadydoes sUgg the absence of a halopefldotrotatedincrease n the orcadenceof onoptesrain rats at doses op to20 Drossthe Usualda honnandose for chrorecor resistant patents In femate race at 5 and 2Obmesthe hheOi inthaldadydosefnr chroracor restetard pahents, there wan astahskcaffyo#{231}mhcant increase in mammary gOod oeopia and total tumor incotence,at 2dtimeo the same doty dose there wan a StOiohcaRy sqnhcant rease in pituhary gtexl neoplana In male m. no statishcallysigniffcantdffferencesm UncAlencesof total tumnrs or specific flimortynes ecre noted Antcsychokc drags etevateprotachn hoots; the otevabonpenrastsduneg thronc ndministraion. Thoon cofloreaspenmentr iothcatethat approobmatelyone-third of human freest cascara are protactArdependent Ar*n, a factor of padentot impeitance Hthe until steady state has been achieved. prescnption of these drugs o contemptated in a pahent witha previouslydetected breast cancer. AlthoughOisturbancessuch as galactnnrhea .q, amenoarhea gynecomasti and linpotence tave taen reported, the diotcalognificance nfelevated serum prnlacbnlevelsniunknownfvr most pabents. Ar increase ni mammary neo#{216}asros has been found in rodents after chroen wiminibahon of anfipsychoficdnag Nelther dtek chides nor epniemknog studes conducted to date, hnweoer, haveshown an assocnhnn betweenchronc idmiontrabnn of these drugs and mammaiytumvdgeveste: the aVadableevidenceisconsidered too tended to be concluoveidthibme (leap to Proq.anc PregnancyCategoryC.Safe use inpregroocyorir women hkelyto become pregnant has not been estabitehed;use onlyH benefitdearfy jusohes potenhalhazardstothefetus. NurelogNathoet lnfavitsshnuktnot be nursed dump dnigtreatment PodiatrIc Uoa:Controted tniatstoestabhofrflesabetyand effechvenessof intrannoscularudministrabonni chntren have not been cOndUCt ADVERSIREACTIONS:Adverse macboos fotowoag the admirestratoanof HALDOLDecannate 50 or HALDOLDecanoate 1HAam those of HALDOLhalvpeddoi Since vastespernince hasaccumutated wdh HALDOLthe adverse reachoirsare reported fonthaf compound as wet asfor halopeddoldecanoate.Mwfihat nictable methcafions,tucalhssue reachom havebeen repvrfedwoh halopeddotclecanoate. ciis m.et Eaha& Sl#{216}ms($)- EPSdufleg fleadiroOnitrahOnof HALDOL)honpeddel)have been reported frequenfly,often duneg the first few days of treatment. EPS can be categoncied generally as PadAnsvnhke symptoms. akathnii or dystoma (inckntieg opisthotonos and cn2Hogyriccrisis). Wink at can occur at relativelytrw doses, they occur more frequentlyasotwith greater severityat higher doses. The symptoms may be contmted withdose reductions or udmimstrahonof anhparlunson drugs such as berrztmpmemesylate USPor tHhenyenrochtundeUSP.ftshoulebeoofwithidpersniteMEPShavebeerrepoded;thednigmpohavetnbedtuconfiouedinsucfr cases. WhdrawaI Emsepid NsoreIocaI $ns - abrupt detconfinuation of short-term ath-psychofc therapy te generally uneventful However.some pabents on malntenance treatment espeflence transient dystunehosigns after ahrud withdrami. In certan cases these are indofingunhabte from ‘TardnieDyntunesa”except for donahue.ft s unknownwirether gradual withdrami wdlreduce the occurrence of these ogns but urtd further eordenceni avidalde HALDOIshoutu be graduallyeithdrawn.Taatlvo DetJosia - As with at anfipsychuhougents HALDOLhas beenassocoted wtffrperslstent dyskinesnis TardNedyOiunes asyndrnmeconstubng ofpotenbaftylnovenOib involuntary,dys#{149} tanehc mmennents, mayappear in some pabentson tang-tametherapyormay occurafterdrug therapyhas beendelconfinued.The dskappears to begreaten nielderlys on high-dose therapy,especratyfemales. Thesymptomsare persisterdand in some pahenfsappearirrewnsthle The syndrome s characterized by rhythmmi rovokintarymevements of tongue, face. mouth or w (e.g., protroslon of tongea puffing of cheetu. puckenng of mouth. cIrce-mg mowrnrents(.Somefimes these may be accom tr invotuntarymovements of eutremdho and the trunk There s no known effectud treatment for tardok dystunenic anfipa’fdnsonagents usually do not alleotatefire symptoms of Des syndmme. Unisuggested that all aobpsychOhCagents be dhiconbnuedHthese symptoms appear. Should ft be necessary to ntnStdUtetreatment or increase the dosage of the agent or switch to a ddferent anfipsychoficugeot, this syndrome may be masked. ft has been reported that fine verncubr movement of the toegue may be an earlysign of tardsle dystunesniand Hthe methcattm nistopped at that fine the fuRsyndrome may not develop.Taattw Dyatoula - Tarthvedystnna not assncated with the above spodmee, has also been reported. Tardho dyntornani cfraractenniedbydel onsetofchormc ordystonc movements, s often pernistent,and hasthepotenbal of becomsrg irreversdae. OIeeIlS E1ods - Insomni restlessness, anolety,euphora agelahon,dmwniness, depresslon, lethargy, headache, conhisnin, vertigo, grand mat seniure and enacerbabon ofpoychoto symptoms indudiug hafluanahons, and catatonk-hke behaofnudstates whtrh may be responrave to drag oethdra aod/ortreatrnent withaobchOiinerg drugs. Body as a Whotc Neuroleptc malignantsyndrome (hitS), hyperpyrextewnl heat stroke have been reported wtfhHALDOL.(See WARNINGS forfurtfrer erformaboinconcenniegNtIS.) Caedlevascati Efto Tachycardi hypotensoto, hypertensninand EcG changes, ndud prtAongabnnof the 01 inteevatand EOGpattem changescnmwith the polymorphousconfigurafionoftorsades do pnintes. I$smaI Eftsc Reports ofmild, usually transient leukOpemaand leokocytosm,minimaldecreases in red blood ceUcourt anemia or a tendencytowerd lymphnmnnocyfnsni;agomutucy1nshirarelyreportedarni only inassociahon withOthermediabOn. I Lles,Eflsc Impanedhwntancbonand/orpurebce. DonRaIoi*DeactIsot Mwtupegukeandamedono macfloes,sotated esofphntosensHMly, tess of han. Endocetas Dlesedsec Lacfabon,breast engorgement nrastalga menstrual irreguhafies, gynrecoanasbaimpotence,increased fibeto, hyperglycemihypoglycerniiaaodhyponatrenna Mntconsbpahon,dtarrheahypemahvidnir,dyspepsi ouoreaandvomhag AatoaooeicReaethiut Dryrnouth. oturredvision,unitary retention,diaphoreste,and pnugisirr. RisoiyEfls Laryngospasnr,bronctrnspasnnand uorreaseddepth ofrespirafion. Special Ssoae Catazfs. rehnOpathyandVioUaldteturbaoces. 4 QUeerCases ofsudden and unespecleddeath havebeen reported inassodabon withthe idmiotetrationof HALDOLThe nature ofthe enidence mattes H imposnibleto determine doflndly what rn Hany, HALDOLptayed in fire outcome of the reported canes. The POSSAlAHYthat HALDOL caused death cannot of course. be erniuded, but ft nito be ked n wind that sudden and unexpected death may occur ni poychofic pahentswhentheygs untreated orwiren tmyamtrealed withOtherantmpychOl(drags. Psad Ewoi Hyperammonerna has been reported in a 5/i ynar ote chat with dtrutiner* an onherdeddteonter of ammonia excre boo, fONhongtreatmerftwithHALDOL. 4 UPORTANT:Fell Smedoitthamakootd as road batote NALD orHALDOLDecanoats praduetsaro admlolstsrW eeproscelbod. Fot*miaNeo oosvor*msaod troataoatrAovsrisaaos,ssslell pescdiaa *noatlot . . TtnJwt.Jrvr HAtflflt Ntstifnrm nv*and1mifn Retercnce: 1. DavisJM, KaneJM, Mrder SR. er a]. Dose HALDOL#{176} Decanoare Packige 1ricrr. McNeil Lyman RC, SakId SR. Anderson CO. RJCIWdS AL 2. Ansixiarion 144th Annual Menting. May C 991; PHARMACEUT1CL M O8HO29B/O2-t4-95 NEWJEROEYOOOO2 response Pharmaceiirkal. o1prophyIcric aiiripsychotics.J C/in Piycbiatry.1993,54(suppl 3):24-30. Spring House, PA 19477. Revised 10/13/92. 3. Ereshefsky1. Toney G. Halopcndoldeunoanc: New Orleans. an dTeaine &sing snratcgy. Prenented an the Arnencan Psyclnatnc La. : SCIOS poaooeceanic*s NOVA 4 - HALDOL Provides the protection no increased with relapse... risk of side from as compared F X T F N I) I N (; P ConSiStent mOSt to oral R 0 1 F C T 10 N therapy FRoI HALDOL#{174} Decanoate (HALOPERIDOL) 1) \1 ‘Ni 1 1 \l l\( INJECTION H (II II effects RFIAPsE 100 100 mg/mL ? 1’ .c I,,. ONCE-DAILY PAKIE PAROXET/NE/-IC! References: GC. Cohn JB, Fabre LF, et al. BrJPsychiatry 1991;159:394398. 2. Cohn JB, Wilcox CS. J Clin Psychiatry. 1992;53(suppl): 52-56. 3. Feighner JP, Boyer WE J Clln Psychiatry. 1992;53(suppl):44-47. 4. Fabre LE J Clin Psychiatry. 1992;53(suppl):40-43. 5. Sheehan D, Dunbar GC, Fuell DL. Psychopharmaco/Bull. 1992;28:139-143. 6. Clayton PJ, Grove WM, Coryell W, et al. AmiPsychiatry. 1991;148: 1512-1517. 7. Paxil (paroxetine HCI) Prescribing Information. 1. Dunbar PAXIL#{174} (brand S.. of parox.tine hydrochiorid.) complat. prescribing information in SmfthKIin. Becham Pharmac.utical. Iitraturs or PDR. Th. following is a brief summary. INDICATiONS AND USAGE: Paxil is indicated for the treatment of depression. CONTRAINDICATIONS: Concomitant use in patients taking monoamine oxidase inhibitors (MAO(s) is contraindicated. (See WARNINGS.) WARNINGS: Intaractions with MAOIs may occur. Givan th. fatal int.ractions rported with concomitant or imm.diately consacutiva administration of MAOIs and othar SSRIs, do not usa Paxiin combination with a MAOI or with. In 2 waks of discontinuing MAOI tr.atmant. Allow at I.ast 2 w.ks aftar stop. ping Paxil b.for. starting a MAOI. PRECAUTIONS: As with a)) antidepressants, use Paxil cautiously in patients with a history of mania. Use Paxil cautiously in patients with a history of seizures. Discontinue it in any patient who develops seizures. The possibility of suicide attempt is inherent in depression and may persist until significant remission occurs. Close supervision of high-risk patients should accompany initial drug therapy. Write Paxil prescriptions for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose. Reversible hyponatremia has been reported, mainly in elderly patients, patients taking diuretics or those who were otherwise volume depleted. Clinical experience with Paxil in patients with concomitant systemic illness is limited. Use cautiously in patients with diseases or conditions that could affect metabolism or hemodynamic responses. Observe the usual cautions in cardiac patients. In patients with severe renal impairment (creatinine clearance <30 mL/min.) or severe hepatic impairment, a lower starting dose (10 mgI should be used. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably sure that Paxil therapy does not affect their ability to engage in such activities. Tell patients 1) to continue therapy as directed; 2) to inform physicians about other medications they are taking or plan to take; 31 to avoid alcohol while taking PaxiI 41 to notify their physicians if they become pregnant or intend to become pregnant during therapy, or if they’re nursing. Concomitant use of Paxil with tryptophan is not recommended. Use cautiously with warfarin. When administering Paxilwith cimetidine, dosage adjustment of Paxil after the 20 mg starting dose should be guided by clinical effect. When co-administering Paxil with phenobarbital or phenytoin, no initial Paxil dosage adjustment is needed; base subsequent changes on clinical effect. Concomitant use of Paxil with drugs metabolized by cytochrome P4llDv lantidepressants such as nortriptyline, amitriptyline, imipramine, desipramine and fluoxetine; phenothiazines such as thioridazine; Type 1C antiarrhythmics such as propafenone, fecainide and encainide) or with drugs that inhibit this enzyme (e.g., quinidinel may require lower doses than usually prescribed for either Paxil or the other drug; approach concomitant use cautiously. Administration of Paxil with another tightly protein-bound drug may shift plasma concentrations, resulting in adverse effects from either drug. Concomitant use of Paxil and alcohol in depressed patients is not advised. Undertake concomitant use of Paxiland lithium or digoxin cautiously. If adverse effects are seen when co-administering Paxil with procyclidine, reduce the procyclidine dose. In 2-year studies. a significantly greater number of male rats in the 20 mg/kg/day group developed reticulum cell sarcomas vs. animals given doses of 1 or 5 mg/kg/day. There was also a significantly increased linear trend across dose groups for the occurrence of lymphoreticular tumors in male rats. Although there was a dose-related increase in the number of tumors in mice, there was no drug-related increase in the number of mice with tumors. The clinical significance of these findings is unknown. There is no evidence of mutagenicity with Paxil. Serotonergic compounds are known to affect reproductive function in animals. Impaired reproductive function in rats (i.e.. reduced pregnancy rate, increased proand post-implantation losses, decreased viability of pups) was found at Paxil doses 15 or more times the highest recommended human dose. Pregnancy Category B. Reproduction studies performed in rats and rabbits at doses up to 50 and 6 times the maximum recommended human dose have revealed no evidence of teratogenic effects or of selective toxicity to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Paxil should be used in pregnancy only if the benefits outweigh the risks. The effect of Paxil on labor and delivery in humans is unknown. Paroxetine is secreted in human milk; exercise caution when administering Paxil to a nursing woman. Safety and effectiveness in children have not been established. In worldwide Paxi/clinical trials, 1 7% of Paxi/-treated patients were 65 years of age. Pharmacokinetic studies revealed a decreased clearance in the elderly; however, there were no overall differences in the adverse event profile between older and younger patients. ADVERSE REACTiONS: lncid.nc. in Controlled Trials-Commonly Observed Adverse Events In Controlled ainical Trials: The most commonly observed adverse events associated with the use of Paxil(incidence of 5% or greater and mcidence for Paxil at least twice that for placebo): asthenia (15% vs. 6%), sweating (1 1% vs. 2%), nausea 126% vs. 9%), decreased appetite (6% vs. 2%), somnolence 123% vs. 9%). dizziness (13% vs. 6%), insomnia (13% vs. 6%(, tremor (8% vs. 2%), nervousness 15% vs. 3%), ejaculatory disturbance (13% vs. 0%) and other male genital disorders 110% vs. 0%). Twenty-one percent 1881/4,126) of Paxi/ patients in worldwide clinical trials discontinued treatment due to an adverse event. The most common events l1 %l associated with discontinuation and considered to be drug related include: somnolence, insomnia, agitation, tremor, anxiety, nausea, diarrhea, dry mouth, vomiting, asthenia, abnormal ejaculation, sweating. The following adverse events occurred in 6-week placebo-controlled trials of similar design at a frequency of 1 % or more. Body as a Whole: headache, asthenia, abdominal pain, fever, chest pain, trauma, back pain. Cardiovascular: palpitation, vasodilation, postural hypotension. Dae’matologic: sweating, rash. Gastrointestinal: nausea, dry mouth, constipation, diarrhea, decreased appetite, flatulence, vomiting, oropharynx disorder, dyspepsia, increased appetite. Musculosklatal: myopathy, myalgia, myasthenia. Nervous System: somnolence, dizziness, insomnia, tremor, nervousness, anxiety, paresthesia, libido decreased, agitation, drugged feeling, myoclonus, CNS stimulation, confusion. R.splratlon: respiratory disorder, yawn, pharyngitis. Special S.ns.s: blurred vision, taste perversion. Urogenital Syst.m: ejaculatory disturbance, other male genital disorders, urinary frequency, urination disorder, female genital disorders. Studies show a clear dose dependency for some of the more common adverse events associated with Paxil use. There was evidence of adaptation to some adverse events with continued Paxil therapy (e.g., nausea and dizziness). Significant weight loss may be an undesirable result of Paxil treatment for some patients but, on average, patients in controlled trials had minimal (about 1 Ib) loss. In placebo-controlled clinical trials, Paxi/-treated patients exhibited abnormal values on liver function tests no more frequently than placebo-treated patients. Other Ev.nts Observed During the Pr.mark.ting Evaluation of PaxII During premarketing assessment, multiple doses of Paxil were administered to 4,126 patients, and the following adverse events were reported. Note: frequent = events occurring in at least 1/100 patients; infrequent = 1/100 to 1/1000 patients; rare = less than 1/1000 patients. Events are classified within body system categories and enumerated in order of decreasing frequency using the following definitions. It is important to emphasize that although the events occurred during Paxil treatment, they were not necessarily caused by it. Body as a Whole: frequent: chills, malaise; infrequent: allergic reaction, carcinoma, face edema, moniliasis, neck pain; rare: abscess, adrenergic syndrome, cellulitis, neck rigidity, pelvic pain, peritonitis, ulcer. Cardiovascular System: frequent: hypertension, syncope, tachycardia; infrequent: bradycardia, conduction abnormalities, electrocardiogram abnormal, hypotension, migraine, peripheral vascular disorder; rare: angina pectoris, arrhythmia, atrial fibrillation, bundle branch block, cerebral ischemia, cerebrovascular accident, congestive heart failure, low cardiac output, myocardial infarct, myocardia) ischemia, pallor, phlebitis, pulmonary embolus, supraventricular extrasystoles, thrombosis, varicose vein, vascular headache, vontricular extrasystoles. Digestive System: infrequent: bruxism, dysphagia, eructation, glossitis, increased salivation, liver function tests abnormal, mouth ulceration, rectal hemorrhage; rare: aphthous stomatitis, bloody diarrhea, bulimia, colitis, duodenitis, esophagitis, focal impactions, focal incontinence, gastritis, gastroenteritis, gingivitis, hematemesis, hepatitis, ileus, jaundice, melena, peptic ulcer, salivary gland enlargement, stomach ulcer, stomatitis, tongue edema, tooth caries. End.cnn. System: rare: diabetes mellitus, hyperthyroidism, hypothyroidism, thyroiditis. Hemic and Lymphatic Systems: infrequent: anemia, leukopenia, lymphadenopathy, purpura; rare: abnormal erythrocytes, eosinophilia, (eukocytosis, lymphedema, abnormal lymphocytes, lymphocytosis, microcytic anemia, monocytosis, normocytic anemia. Metabolic and Nutritional: frequent: edema, weight gain, weight loss; infrequent: hyperglycemia, peripheral edema, thirst; rare: alkaline phosphatase increased, bilirubinemia, dehydration, gout, hypercholesteremia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, SGOT increased, SGPT increased. Mus. culoskelatal System: infrequent: arthralgia, arthritis; rare: arthrosis, bursitis, myositis, osteoporosis, tetany. Nervous System: frequent: amnesia, CNS stimulation, concentration impaired, depression, emotional lability, vertigo; infrequent: abnormal thinking, akinesia, alcohol abuse, ataxia, convulsion, depersonalization, hallucinations, hyperkinesia, hypertonia, incoordination, lack of emotion, manic reaction, paranoid reaction; rare: abnormal electroencephalogram, abnormal gait, antisocial reaction, choreoathetosis, delirium, delusions, diplopia, drug dependence, dysarthria, dyskinesia, dystonia, euphoria, fasciculations, grand mal convulsion, hostility, hyperalgesia, hypokinesia, hysteria, libido increased, manic-depressive reaction, meningitis, myelitis, neuralgia, neuropathy, nystagmus, paralysis, psychosis, psychotic depression, reflexes increased, stupor, withdrawal syndrome. R.spirato‘V System: frequent: cough increased, rhinitis; infrequent: asthma, bronchitis, dyspnea, epistaxis, hyperventilation, pneumonia, respiratory flu, sinusitis; rare: carcinoma of lung, hiccups, lung fibrosis, sputum increased. Skin and Appendages: frequent: pruritus; infrequent: acne, alopecia, dry skin, ecchymosis, eczema, furunculosis, urticaria; rare: angioedema, contact dermatitis, erythema nodosum, maculopapular rash, photosensitivity, skin discoloration, skin melanoma. Special Senses: infrequent: abnormality of accommodation, ear pain, eye pain, mydriasis, otitis media, taste loss, tinnitus; rare: amblyopia, cataract, conjunctivitis, comeal ulcer, exophthalmos, eye hemorrhage, glaucoma, hyperacusis, otitis extema, photophobia. Urogenital System: infrequent: abortion, amenorrhea, breast pain, cystitis, dysmenorrhea, dysuria, menorrhagia, nocturia, polyuria, urethritis, urinary incontinence, urinary retention, urinary urgency, vaginitis; rare: breast atrophy, breast carcinoma, breast neoplasm, female lactation, hematuria, kidney calculus, kidney function abnormal, kidney pain, mastitis, nephritis, oliguria, prostatic carcinoma, vaginal moniliasis. Postmarketing Reports Voluntary reports of adverse events that have been received since market introduction and not listed above that may have no causal relationship with Paxil include elevated liver function tests (the most severe case was a death due to liver necrosis, and one other case involving grossly elevated transaminases associated with severe liver dysfunction), toxic epidermal necrolysis, priapism, thrombocytopenia, syndrome of inappropriate ADH secretion, symptoms suggestive of prolactinemia and galactorrhea, neuroleptic malignant syndrome-like events; extrapyramidal symptoms which have included dystonia, akathisia, bradykinesia, cogwheel rigidity, hypertonia, oculogyric crisis (which has been associated with concomitant use of pimozide), tremor and trismus; and serotonin syndrome, associated in some cases with concomitant use of serotonergic drugs and with drugs which may have impaired Paxil metabolism (symptoms have included agitation, confusion, diaphoresis, hallucinations, hyperreflexia, myoclonus, shivering, tachycardia and tremor). There have been spontaneous reports that abrupt discontinuation may lead to symptoms such as dizziness, sensory disturbances, agitation or anxiety, nausea and sweating; these events are generally self-limiting. DRUG ABUSE AND DEPENDENCE: Controlled Substance Class: Paxil is not a controlled substance. Evaluate patients carefully for history of drug abuse and observe such patients closely for signs of Paxil misuse or abuse (e.g., development of tolerance, incrementations of dose, drug-seeking behavior). BRS-PX:L8 SB SmsthKlsn. Philadelphia, Bescham PA 19101 JANSSEN .==.. Business Information Psychiatric Services is a monthly interdisciplinary journal published by the Amencan Psychiatric Association, 1400 K Street, N.W., Washington, D.C. 20005. (The journal was named Harp ital and Cornff_ Psych untilJanuary 1995.) Editor: John A. Talbott, M.D. Managing Editor: Teddye Clayton Editorial Office Phone, 202-682-6070 Fax, 202-682-6189 Editorial Inquiries: Joyce Ailstock Manager: Sales Nonpharmaceutical Advertising: Brian Buono APA Periodicals Services 1400 K Street, N.W. Washington, D.C. 20005 Phone, 202-682-6329 Fax, 202-682-6347 Brian Buono and Services (see address Directory above) Classified Advertising Rita Bellinger APA Periodicals Services 1400 K Street, N.W. Washington, D.C. 20005 Phone, 202-682-6250 Fax, 202-682-6347 Department American Psychiatric Association 1400 K Street, N.W. Washington, D.C. 20005 Phone, 202-682-6240 Fax, 202-789-2648 Circulation Director: Beth Prester Assistant Director: Jacqueline Young Marketing Director: Elizabeth Flynn Circulation 858 copies (issues from previous volor earlier issues in the current volume) are available for purchase from the circulation department. Single copies are $6 in the U.S. and $7 outside the US. Back umes Reprints Address Reprints of single articles are available from the APA library; phone, 202-6826080, or fax, -6248. The charge is$10 per article, or $5 per article for APA members and staff in organizations affiliated with the Psychiatric Services Resource Center. Bulk reprints of journal articles are available(a minimum of 100 copies). Allow four to six weeks for delivery after placing an order. For a reprint order form or other information, contact periodicals Subscription services ington, Pharmaceutical Advertising: RaymondJ. Purkis 2444 Morris Avenue Union, NewJersey 07083 Phone, 908-964-3100 Products Subscription Rates Except for psychiatric residents (see below), the journal is available only through paid subscription. One-year subscniptions (12 issues) within the US. are $40 a year fbr individuals, $60 for institutions, and $20 fbr students. Subscriptions outside the U.S. are $60 fbr individuals, $80 for institutions, and $30 for students. (Copies are thipped to foreign caintnies by air freight.) Make checks payable to APA and mail to the circulation department at the address at lower left. Credit card orders are accepted by phone; call 800368-5777 Periodicals Services Phone, 202-682-6250 Fax, 202-682-6347 Director: Nancy Frey Advertising Production Laura Abedi Advertising for Readers (202-682-6240 D.C., in the Wash- area). Changes and Inquiries For address changes or inquiries about subscription status or billing, contact the circulation department. For faster service, refer to the seven-digit personal I.D. number located above the name on the mailing label. For address changes, include both the old and the new address. Please give at least six weeks’ advance notice ofa change ofaddress to ensure uninterrupted service. Group Electronic and Microform Formats PsycbiatricSeriices is available in CD-ROM as part of the American Psychiatric Electronic Library. For more information, call 800-368-5777. The journal is also available in microform and microfiche from University Microfilms International; for more information, call 800-251-0600. List Rentals The journal’s Subscriptions health fcilities Mental can receive at 202-682-6250. and organizations groupsubscniptions nc Services at discounted toPsychiatrates through APA’s Psychiatric Services Resource Center.For more infbrmation, contact Mary Ward; phone, 202-682-6173; fix,-6348. Subscriptions for Residents Psychiatric residents may receive a free subscription to Psychiatric Services throughout their residency training. Residents requesting a free subscription should send their name and address along with the name and location of their residency program, their year of training, and the name of their training director to Susan Kuper, APA Member Services, 1400 K Street, N.W., Washington, D.C. 20005; phone, 202-682-6062; &x, -6385. Missed Issues and Back Copies Please notify the circulation department of missed issues within two months of the publication date and allow two to three weeks for delivery. Psychiatric Services subscriber list can be rented robe before the list is provided. Call 202-682-6158 to request a list rental brochure. formailings. Asample ofthematerial mailed must be approved by APA Advertising For advertising rates and other contact one of the advertising information, sales staff column. members listed in theleft-hand All ads are subject to editorial ap- proval before publication. APA accepts no responsibility for claims made by advertisers. The acceptance of advertising does not in any way constitute APA endorsement or approval of any advertised service or product. Permission to Copy or Reproduce APA freely grants permission to photocopy material from the journal in limited room quantities use. for educational Reproduction or class- in any other form or for any other purpose must be approved in advance byAPA. Formore in- formation, September contact 1995 periodicals VoL services. 46 No.9 RAPID STABILIZATION AND TREATMENT BIPOLAR IN OF DISORDER PSYCHIATRIC THE EMERGENCY SERVICE 12noon 2:00pm - Fday,October6, 1995 Industry supported luncheon Symposium 1 CHARIPERSON: Pnin 1.FORSTER, M.D. PRESENTERS: PAULE.KFIX,JR.,M.D. MARKA. FRYE, M.D. I I - j L A SELECTIVE SEROTONIN INHIBITOR REUPTAKE DEMONSTRATED COMPULSIONS RAPIDLY EFFECTiVE IN RELIEVING IMPRISON PATIENTS’ AND MINDS1* BLOOD LEVELS; HALF-LIFE’ INCIDENCE LOW STEADY-STATE ACHIEVES SHORT OBSESSIONS THAT FAVORABLE OF AGITATION SAFETY (2% vs 1% for placebo)’ PROFILE #{149}:#{149} Relatively low incidence of anticholinergic side effects in controlled trials of OCD and depression, LUVOX Tablets vs placebo’: dizziness 11% vs 6%; constipation 10% vs 8%; dry mouth 14% vs 10% #{149}:#{149} The most commonly observed adverse events compared to placebo were somnolence 22% vs 8%, insomnia 21% vs 10%, nervousness 12% vs 5%, nausea 40% vs 14%, abnormal ejaculation 8% vs 1%, asthenia 14% vs 6%’ + Concomitant use of LUVOX” Tablets and monoamine oxidase inhibitors is not recommended’ FLEXIBLE Initial DOSING Dose: 50 mg once #{149}4.H *Lj j a day HS 50-mg tablet #{149} Increase i#{174}-mgtailet #{149}BID dosing SAFETY COMPREHENSiVE Dose Range: DATABASE 100 to 300 mg/day by 50-mg ilicrements recoI1mended as needed for over 100 l1g/dav (World4de Exposure for Reporting Overdose #{149}#{149} Data from 40 countries + Over 9 million patients + More than 37,000 patients studied in clinical trials treated LUVOXT IIuvoxamine maeate TARGETED TREATMENT FOR OBSESSIONS AND Effectiveness not established beyond 10 weeks in controlled ulals. tprescribers should write the smallest tablet quantity consistent with good patient management to Please see brief summaty of prescribing information on adjacent page. every 4 to 7 days COMPULSIONS reduce overdose risk. )‘ I I IJAVT’ LUVVA (Ihvsoii..uIsols)IsIs BilsiSummosy (Ffo PresolbisgWonmohi *Io #{149}KIO N di.p: hh*LujthudsuO.th oxkogs imert) ILuA (2isthmauhiisosaiRJm’lmmidisholithmolui hahas- 1hiMolthmdLusssonirn idoacsi & isoiisolsd pssRrI thsW ithmm tesithos.mmizsdbydspsmonmsumrismmmmmdk sIkosydUMLu1isossv Ihsd.osthhu(sDSM1It mCCsLTh ksdrli. auA (minol 1WhisolUAIsisJI) ss ts.ol5u. UuAO.I,O3, 2.aud4thnuthsa.iushmaudoldoososoufm’hi NuidosmRedoMugdhctonthshMoswpv#{231}suiAInothndsdoit mugmihiosohi hlws spdp1si osd/mmpsAI pspos#{233}& osdEolOIIdbIhiOR #{241}Mnuidhifmh#{231}ianm,L.kommthos1Oauslhisi hmauol#{224}hntcld thudS. 2*uId 1tOsjtwsm’ d.aumi1olithhdthuolhsimmdthusr. Thauaunoothmosdaukm*sdLua sgmi1aum’ osauddsthugkedmflhidut tOIflRMNIKA11OIS (s#{243}iolosdhihiumosss)ohMthWSXTsiuR6snisk ohisdsioauftmi. IUNGS Phihi.mol.mIkAI...OoIsoss. ... ud. Iin ( osWASAI his, his. iurb i. d iu aiss .idi.s.moiiiOthv guMadam’ . S Nmklsisn Mwth&u6osaussdmksaoskssin& osmosis h#{224} 1WA.II ‘mouh.,h.si#{224}dhicsisammNSIIA4hmm’mo . psS v d Ihiks .us#{225}u .(iiii, .d u.thuh h,s..d. *udiuIu.,.lu#{225}#{232}sQTpith..dNr- h4,iu..u _____ flu uuiu h (mssquu *S11IACflUS6 Mmsmdm dbs-Th haWsos. hCSuINUidhi iS? hiZOOZSPmiauhihdWsddOos uuissmunoa1hiMds#{224}thhisihm (&uiuioz adthAs.amai.mksodhicm tel%)s.odthOauOossdmsidsmdh1s.,k 4q mmmi auo0 #{227}ma,irs#{225}* s,swue#{243}Oidmid,thoos * #{232}ynma* ommIUi #{224}mi. sibsu. M#{224}W.os h to. 1 siAIosolthmossosap#{231}miis25%diosmsmnsss, m#{227}d*dR*mmm#{233})MR ?bIAdIImoIosS dadki.is (5On#{231} moskisiidai m12hinsnahimohWNi i.sdthsc#{231}k1h.w Iosrad &iUm#{224}iis, odthmisn.udssssid UM5 1hs hidsnUs mm kthsMhk Othugth.s1 othM #{241}modfl UMX LbSIIS**1 (sibi ii#{225}thjsdsidiossy IIISSthhIId. mssessmch XLuiishsis ------.----.--.--,--..,--.--.-.----.-.-------.-----.--.-,---.--, hPOUitdhid3ImcHOA1isSI,d.is.mi i.IoiasidWit (i)mOoschi#{231}.frcmbs.hias#{243}ammo mmossmdos 12) ____ 5isui.1*gs$i II5ROn5ntI1SVSIfl Thausau5auhimdm bWS.ps (1)mi#{224}mgskmmhiuuauosnos 0 hmlog mduOur#{224}dmowimiiummbitarAosss.iism#{224}mosdphi#{226}i ,cG5 (ososmdImnmii.jmhprnospdionisan&Ds.Ithps.Oi#{225}os (1) miosdiospfromhii.am.amt5G thhiis 12) &*ss.imnsdsaissdjeak h t SEAIlBfl.GBflADVM VTUOUBIOIA1SITDYSYS1W*OMSUISSlSI POPIIA11UISCOU N 5osaua*mv#{216}ociksbymIsolpsrcs*p):IYASWHUth His fl.t2Lu;Mthosti4vLd);FWmm(3vL2);OC2vLi). CAIDIOVASOJIAA: PiHHoia(3v&2). UIGHSTMSYSIa tiiosi#{224} (6v2);*s* (5v 2); Fhiiscs (4 3);lccthIhiids’ (3mM; Dthoo (2 i).NYCIJSSYS1Scnmohsos(22vsJ);hmsmX 121 1Lu;LuyMsih(14v1O);Nsaumisos(12s&5);SEum(11m6);him(Ss1); . osQvsM;hiumosiLuks(21).hinvmos12mi).O6SlhiOxl21). STS1aUipbyolasfl5); sisQ 1)hiQO). UIk Sau(73). IO*LISlk *PmmdamI3 1);MAIp122. UlOSBISlI Osamsi 1);hasg12Lu;UiisyUiiOmfl mit. ksLIMXith Os b OUipUN fl,osuODthOuatauIoldrnasm,mosconossd audsiumthv MOtSOiI Is*sd&Mssrit ms&*ds*h#{231}r.ssisM sds#{231}i O2%d&rispI thsiui1sImiossiwm ka ms.yhsui ahithossthpiidikcki duiisos*uiusi PhmoICi&dS lAssios). Rsosi*sDmdLudisuii Iths adsi A&i.fmmhOIII1sos.osd 15k h2uis.tholommmdolobimy di%wmom,osdaummouha*mil,jo#{226}spauai#{231}pOuis*solid Uts.thoduajmksm*hiODhi(iOau#{225}l moshi(6auimmdaudiadiSLu3Sm/ tham*,pmmn,osm.othudu hdolhsiassmmmnosdus.isismmsthiiiosit hipoisdauauisidsismdudchimdUdis.yNmhi dossd1Onazs *sAdnctntsw#{243}iismt flu ddmosd5%mgsosudhsisiosIwks$oc i.osi#{225}ae iomm nmmmau haus au thsM nosidloshii osmdbsos.nmvh mmauta3Ss#{231}dus6mi#{225}IE o.l.#{232}sagsau#{231}s iO3OOs hWm#{224}IdbUMLuI - . OhnpthholhiosR*uhist#{241}immis.u#{224}t hw#{243}ioosdUXTsdthuipmnisidysithk Lust Tthhi uth . hI 1Rn#{190}1k 2 in sdthm”c’ Th is m’ossiauos#{224}.aud ‘ . siunauaud.dWSXTOismOaLuhthishi Thd.mmmidbINuhZiPPismUOOidV i3tt mmmi ?4NS#{225}Ni$ CR I h Nmm.Ith1UiPSIUO TlMmICHIommoPwmaNS. Oils p,imo* mp himiudhi. (thm*PWTrJ6.h5_ctsa) P...:t:m zipnnhi*isL osddslw PIMk Ui. S#{225}smhotmimudL1MIisrnrn&athJ#{225}bi, 18ysmsdhimolbsmnssOAIut GuIk Ihs 23O#{216}.thpsiosg al.dpisOosuUMLuhiIauu6Smmdosm’ hmauO ni hiOh.zihi Uip hi. L_*iJ I 1i4 .,.e.... ThUd.IhL Nps.osdmhs.osumoIuuuu! 2 mmksh.IdhUhi. sdPRE(MIflOlIS). XTsiaumi*n&mdss thoOhrnihimosthiI.oosdaosmt thmmaosmmis.hi*thsims.,uiosshs.i&1as.ans. hIN.*CIV. di*#{224} hohissmdiv yPO.tdmiM ms. ‘himmmos&#{225}* s; disdiijtd*s; IsaOIOISUm4UiIhI.FPI...LUi,Is#{224}Ih.d IS.PS(MJflLuISReiim) WITRs (11Shi?olIolSAsMb 5His5Rmm$thmithi.thONIdiksck*LAylOISdiis5XHOI5 uMtIo ‘hasi ‘siduabs.dass.sdhipO .iQos,OspsmVhii WStTO kdthoI*mithmio A1 miipdthiandmai hd.thnai.tathdam.asosndmdcOSWibmo l#{226}usis,ybsss itmauoswkkthoosmuuans#{224}t ,, hisosdisis m* Sip v v Akmoslasdby CyN#{224}.P454 hipm snopnonauionhdmthssidolamdos)gsmmth.dosisosd.ndogmnszconoondi mmauhisv.Ouauam4thk Is. osohoimds mSid$nuiuut mauldomsolmisni Mmponsdssawsaui#{243}jddiodmkshios, s)thd#{252}Imoeup misd Ndh hp* eptohonu P450((ff450) fluosOsknodIdssnmmonQ hi nuAnuhihi thsmcIosmsi Si) thnununH#{225}sodykHdmtth .ml#{224}thmthaIgmmmiahidmmm6inss.p*ds.honihs.hismi**sdHmdas. amos )ausii.itamosthaumupstdrnsaooshsanusol lkIa,t 4chL ithI,oIls6 NO*ImU#{224}IhidI sihi. It ha ISis #{149}st. isrnsi SisaII6 S..aIN6& r Aasy ish hii.mW aSys hmLuudki nncki* imcus aiss n s n sth fri. agLussi thaimst m a#{216}is hdaT LlVr isat smiWii Ssvts I, miais.d IcOthI*OndIMsaIs sAs (sait &isun msisi cana *i (5Ou#{231}kth #{224}dis *Lui4id ithispckMsw isi. mI s crsbsxziit siusminaoummdaissansi, Akr ocIsdw. Uusad S*a* luihi mins kkAiisis*(1Csi: S#{243}i.*.oi.sd *ni**.tthsc, kssa hithas) .*s hi hi racid in .sdisiismasspsa Thsr &,i.i.ins m#{227}is s hso* *#{225}iss)&isismisndsois AIs OjisaTsm#{224}s IS Smoki&mdo 25%rnasissrnthsnssthohsd&mi. CMp.s#{225},IuIqik,kup#{225}..sidhs* flwsinoM$mcsdiiodIt thisthsn 18dsLu=8)m**siIy lSscth*ki ,no.isnoks 1Snsd ethsp mack shuusss t.#{243}) simus dim thhi hss#{216}ky. thp.sc. ssonflo. thdupmduu, d*iis hpothhi* aI* sia. hirthiolos. ioa.sd sthdui. uii.di*hi.t maui fpsMsm mm#{252}m*dau.t 1hidosthsmsrthsdhmos *hisympodsdadsuss 2hidonthsm’#{232},dhi sw #{216}s UMLuIIhSdsihsWS hioosad mm mm11*othsios Ibt Sss$IIPIG do 1.25n*si*wso&.d 1hiyaTC1k Ireacm Ih,e.sisckEd .rn Ihs#{225}s) 1hRmmdi Ej O61N ,,i#{243}os * sad hksMo mis. ssIodkmod)on hyposi*smi mi#{224}sm,sdfrIje, mm#{232}iuuthidau&osauoimsimtoss)dkmskoloa CAILulOSk Fs)i.himOOi 3E1252 Rev 1195 m26 him) mmdi thm’mthSipmaumiammbcmnudamond160mW9onc th.mminoshmnudddoisamomajn9bu k*swtsw (ooasd lcps LuSt kthlm (ooflios dhiis HiL5yI #{225}hiss#{231}Ins.mpsssih SssIIIGS phinoconus*b msism*ks .ythi Nsri..Stsmsisdthuotn*msKNsiadm5MM* - hsIc4dDZI*hOVSbS. ms*i#{216}ssThndi (ssaa t mc kCIUiIthIhis 1r hibeis st msihi.Nhp,Lu.* Is Ths.s.d240nsmdmmd6thnm UiihimdumisuposIdmmohmmdmsmoissmmams.osm.d* 1. L!I1 SOLVAY 806.VAY 0 aud audwimmaua mhisd U miLu&i1vayPtauhs PHARMACEUTICALS Geo00a 30062 1995, Soivay Phvanamuucdi In All ris)om aumsw& 999217 U3863.O0 TheL1pohiCem#{231}s.y Iammso, MI 49001 Sspisnth 1995 Saturday, Boston \Villiam Marriott Copley M. Glazer, MD, Chairperson Associate Clinical Professor of Psychiany Yale University School of Medicine New Haven, Connecticut Jerrold F. Rosenbawn, MD, CChafrpesson Chie#{128} Clinical Psychopharmacolor Massachusetts General Hospital Associate Harvard John Professor Medical Unit of Psychiatry School, Boston, Massachusetts P. &ighner, MD, FAPA, Discussant President and Director Feighner Research Institute, October San Diego, California Place, 7, 1995 Grand 7:00-10:00 Ballroom, Understanding andAdapting to the Pansdigm #{163}I)ft: Passive Prjiers to Active Purchasers MaryJane Engjand, MD PM Salon De DanieIJ. E, 4th Floor DLsebiliy andthe President, Washington Business Group on Health President-elect, American Psychiatric Association Washington, DC EmployeeAssistance First Chicago Corporation Mjunct Assistant Professor DePaul University, Chicago, The Psychiatrist asAdvocate Allocator of Ciwe Jerrold F. Rosenbaum, MD William M. Glazer, MD The changing dimate in US health care delivery means that psychiatrists must reassess the manner in which they have treated patients. This represents opportunity. A case presentation will illustrate how the psychiatrist treating depression can and Department of Psychiatry and Behavioral University of Washington Medical School Seattle, Washington Sciences r-’’ Pyschiatric by an unrestricted from Eli Lillyand Company Supported Association educational grant -‘= Li Illinois ofcaie patient advocate. of Depression Program Director, serve as both an allocator Collaborative Treatment in Prima,7 Care WayneJ. Katon, MD Professor, Sponsored by American Idsiatrist PhD Conti, and I #{149} iri irm ;ijjii . hirt.ji IrnFbT SOURCEBOOK MAiu OF ADULT STRATEGIES ASSESSMENT S. Schutte, Ph.D., and John M. Malouff, Ph.D., J.D. with a Foreword by Alan E. Kazdln The first text to present actual scales on a wide disorders. including user of their psychometric properties. reviews 70 of the order most popular paralleling current the structure report, observer-based. A volume in the series 0-306-45029- 1 /467 adoption text and Applied pp. EVALUATING and Features over assessment devices in an of DSM-IV. Provides sell- Marriott Hotel-Airport St. Louis, Missouri 1995/$65.OO of six or more copies: MANAGED HEALTH The Fort SERVICES Bragg Experiment by Leonard Bickmn, Foster, $42.50 each MENTAL To obtain additional information and registration material, please contact: Ph.D., Pamela R. Guthrle, Ph.D., Ph.D., E. Warren Lambert, Ph.D., Wm. Thomas Summerfelt, Ph.D., Carolyn S. Breda, Ph.D., and Craig Anne Heflinger, Ph.D. The first comprehensive study of a managed behavioral health plan that reports on the quality. cost. and effectiveness of a system of care for children and adolescents with mental health and addiction problems. Based on a E. Michael five-year gram evaluation funded questions vices about their and of an by the the delivery 0-306-45044-5/219 text price million the demonstration experiment effectiveness in community of pro- raises mental Gary V. Sluyter, Ph.D., MPH. Mental Health Leadership Training Program Missouri Institute of Mental Health 5247 Fyler Avenue St. Louis, MO 63139-1494 Phone: (314) 960-2791 E-mail: mimhgary©mizzoul .missouri.edu critical health ser- settings. + index/il1./1995/$42.50 pp. adoption $80 Army. on orders of six or more copies: $26.50 each Now published by Plenum Press! SUBSTANCE ABUSE Journal of the Association for Medical Education and Research In Substance Abuse Editor-in-Chief: Marc Galanter, M.D. Original therapeutic abusers substance articles cover interventions #{149} medical abuse Subscription: #{149} training #{149} behavior health studies 16. 1995 professionals of substance drug abuse. #{149} and more. (4 issues) Institutional rate: $150.00 in US/$175.00 elsewhere Personal rate: $48.00 in US/$56.00 elsewhere ical studies, reviews. timely Subscription: Volume review 7, on a wide range and/or treatment articles. 1995 results case . Raises . Staff U Flexible format for all mental Inexpensive and fun U ANNALS OF CLINICAL PSYCHIATRY The Official Journal of the American Academy of Clinical Psychiatrists Editor-in-Chief: Charles L. Rich, M.D. Provides up-to-date information regarding the phenomenology with mental disorders. Includes tinven1 the wheel? Zfry a new approach ilu#you can easily to meet the needs ofyour client& Why group adjust with problems associated among specific groups Volume din- book (4 issues) %\_of Book afree Plenum prices are 20% higher #{149} Preventing sample copy Press journal! outside PLENUM Spring Telephone 864 PUBLISHING Street, orders: New ABC’S SKILLS NY health settings #{149} Handling Hassles #{149} Being call orsendfor Each Course a/roe is $45. brochure. Telephones ACURRICULUM FOR LIVING CORPORATION York, competence teachers a Friend #{149} Managing Money #{149} Handling Anger #{149} Being Creative Mental illness Accidents and Crimes : 71&4303353 1.800925-8025 FAX: 718-931-7307 US & Canada. Liuun 233 improves ABC’s #{149} Keeping #{149} Handling Please Sendfor any and can be instant Courses: in Shape Medication #{149} Making Decisions #{149} Caring for Children #{149} Understanding 11 of issues of people of controlled reports, and self-esteem or clients Special Instructor and Student Guides. Innwathte Roleplaylng Card Games. Institutional rate: $162.00 in US/$190.00 elsewhere Personal rate: $48.00 in US/$56.0O elsewhere (_ 8-io, 1996 MAY clinician-rating measures. Clinical Psychology. + lndex/ill./ price on orders of range instructions mental CALENDAR! Second NatonaI Conference on Total Quality Management (TOM) in Mental Health by Nicola adult YOUR 10013-1578 212-620-8000/1-800-221-9369 Psychiatric Services Jack F. Wilder, M.D. Education Program Albert EiftstcIn College of Medicine 1300 MorrIs Park Avenue Mental Health Bronx, New York 10461.1602 September 1995 Vol. 46 No. 9 Two Panels of Outstanding at the Institute C F, F ( )N \ )t U UUUUN M\UUI()H 110 H \lIN(IU\ M I UN, F UH \\ H OIU P 6. U C \I t ur ( C, ( N F udokL, M.I ). I I\( .1 ‘I III) \i hul lie kihn, te &U I (. F \( I )uI; : ii \.I). \ “LI). \ 1,1). i )I , \UI)I 1 0 Ht )J) )I’I IN( )\ , UN \ ., 01 VI J &), ()IU I N RI \NI) . \ U FOI()N 1 \U). U ( ( S F. HiJe, J-( 1 \NJ) UN Services ( )( )U (UFIU \ , APA on Psychiatric U \IN: Robert S 1995 Speakers F 1 JUl11) kIN (:U\U FkI NT \U VII \k\VI Ruhcrt \.\. Hir’.hkId, \i). l(TItl, Ii)) I )ni?i II ( II \1J ). \T.I).., \\,lJln. I .i TI N ‘.1 I tII, VI.!). UT VI U IN: I I I i I Mai1 \ IIII\lIJL!iJhUmJII\ 1 I n 1 nami Ih,I). Calendar For a free listing ofyour meeting in Psychiatric Services’ monthly calendar, drop us a note giving the details of the meeting-sponsor(s), indusive dates, location, type ofmeeting (workshop, conference, annual meeting), theme or topicarea (:fapplicable), and t/#{231} name, address, andtekphone numbe’t of the person to contact for mote information. Because of limited space, only meetings consideredofmost intercit to the readership will be listed. All notices and changes must he received no later than two months before date ofpublication (for example,June 1 for August publication). Correspondence sbouldbe addressed to Cakndar, Psychiatric Services, American PsychiatricAssociation, 1400 K Street, N.W., Washington, D.C. 20005. Healthcare, 108, Portolla 4370 Alpine Road, Suite Valley, California 94028; ida. September rial for 27-29, mental HIV health clinical tuto- professionals, sponsored by the Florida Mental Health Institute, Tampa. Contact Patricia Cleveland, Dean’s Office, FMHI, University of South Florida, 13301 Bruce B. Downs Boulevard, Tampa, Florida 33612; fax 813-974-4694, 813-974-4699. September 28-October 1, West Coast geriatric psychiatry conference, sponsored by the University of California, San Diego, Hotel Del Coronado, San Diego. Contact Cass Jones, Professional Conference Management, 7916 Convoy Court, San Diego, California 92111; 619-565-9921, fax 619565-9954. October 19-22, annual meeting, Psychiatric Association, Empress Hotel, Victoria, British Columbia, Canada. Conact Alex Saunders, Chief Executive Officer, CPA, 237 Argyle Avenue, Suite 200, Ottawa, Ontario, Canada K2P 1B8; 613-234-2815. September September and Central crossroads, 20-23, Eastern sponsored conference on Europe at the by the World Prague, Czech Psychiatric Association, Republic. Contact Professor Jiri Raboch, Dr.Sc., Department of Psychiatry, First Medical School of Charles University, KeKarlovu 11,12821 Praha 2, Czech Republic; 42-2-29-10-83. September conference fits and aged and practice in the era of mancare, sponsored by CentraLink the Institute for Behavioral Healthcare, Mathios, 866 20-24, national dialogue on mental health bene- Dallas. Institute Contact Nicole for Behavioral October 2-5, national mental health cultural diversity conference, sponsored by the U.S. Center for Mental Health Services and the Ohio Depart- ment of Mental Health, Cincinnati Convention Center, Cincinnati, Ohio. Contact William Coom, Public Affairs Coordinator, Hamilton County Community Mental Health Board, 801-A West Eighth Street, Cincinnati, Ohio 45203; 513-632-7152, fax 513-632- 7159, TTY sponsored University 513-632-7166. 5-7, annual meeting, Compeer, Holiday Inn Independence Mall, Philadelphia. Contact Bernice Skirboll, Compeer, Monroe Square, Suite B-i, 259 Monroe Avenue, Rochester, New Palm Beach, Contact Ph.D., by of South Carlton 415-851-8411. September Canadian adults, the Medical Carolina, RitzFlorM.D., Manalapan, F. Randy Sallee, ACCESS Medical Group, Ltd., Salem Lake Drive, Suite A, 3880 RDF Long Grove, Illinois 60047-7676; 550-0090, fax 708-550-0095. 708- October 6-8, annualmeeting, Amencan Academy of Clinical Psychiatnists, San Diego. Contact Alice Munoz, Executive Director, AACP, P.O. Box 3212,San Diego, Califbrnia92l63; 619298-0538. ** October 6-10, Institute on Psy(formerly the Instiand Community Psychiatry), sponsored by the Amencan Psychiatric Association, Boston Marriott Copley Place, Boston. Contact Wanda Sheridan, Coordinator, IPS, APA, 1400 K Street, N.W., Washington, D.C. 20005; 202-682-6314. chiatnic Services tute on Hospital October 1 1-1 3, conference on capitadon and at-risk contracting, sponsoned byCentraLink and the Institute for Behavioral Healthcare, San Diego. Contact Nicole Mathios, Institute for Behavioral Healthcare, 4370 Alpine Road, Suite 108, Portolla Valley, Califbrnia 94028; 415-851-8411. October ference sponsored Addiction 12-15, eighth national conon nicotine dependence, by the American Society of Medicine, Marriott at Eaton Centre, Toronto. Contact Sandy Metcalf, ASAM, 4601 North Park Avenue, Upper Arcade, Suite 101, Chevy Chase, Maryland 20815; 301-656-3920, fax 301-656-3815. October York 14607; 800-836-0475, fax 716- 325-2558. October management peractivity 6-7, conference on practical of attention-deficit disorder in children Psychiatnic October integration tion approaches into the treatment of chronic pain and insomnia, sponsored by the National Institutes of Health, Natcher Conference Center, NIH, Bethesda, Maryland. Contact Conference Registrar, Technical Re- hyand Services 16-18, conference on the ofbehavioral and nelaxa- (Cantinuedon September 1995 VoL page 890) 46 No.9 Because patients are frightened by their positive symptoms -b,-- ii L Positive Delusions * Conceptual disorganization Hallucinatory behavior Symptoms Blunted affect * Emotional withdrawal * Poor rapport * * * Excitement * Passive!apathetic social withdrawal Difficulty in abstract Grandiosity * thinking * * Lack of spontaneity and flow of conversation * * Stereotyped thinking * Suspiciousness! persecution Hostility * improved significantly within group from * p<O.05, baseline. Within group companson ofschizophrenic patients receiving risperidone 6mg/day in North American clinical trial (n=513). The Positive and NegativeSyndrome Scale (PANSS) in its entirety also includes 16 general psychopathology score items; therefore, condusions comes of individual items should #{149} Information brief summary of Prescribing adjacent to this ad. Pharmaceutica JANSSEN Inc. 1995 12-3-4-mg . .. RSPERIDONE as to efficacy outnot be drawn. Please see the ©Janssen Negative Symptoms JPl-RS-123A 3SrntthKIrn Bicham A first choice in psychosis. r A first choice in psychosis. RISPERDAL (R)T 8sfo($ ptSicrIbin consult compises prwcflbln9 Information of INch thsfo1IowIn isa biW summary. lOCATIONS *NUSAGE: RISPERDAL’ dicaIed for the management of the manlestations 01 psych* csoniers. CONTRAINDICAT1ONS: RISPERDAL is contraindicatod in patients wfh a ;4ren8tMtYtoe*uc1 Srome (NMS) has repoflsd m eociion ofth wd*ychofE ugi f a _of req oW bsensof ofler mcoryfrom NMS, the poen re#{241}rockiofon of chug therapy iodd becekyalnsidBte The perf thoiAd be carikfmonore sice reailTencNof NtIS havebeen repods TM A syndrome of polerdiaNy breversible, bwontaty, dysidnedc movements may devek#{231} rn ds treated ofth aofipsych* d,u Mhoi4 the prevalence of the syndrome appears to be highest among the eldedy, especially elderly women, ft e dlleto rely iqton prevelen estimalee ptecIc at the bcep. of bpeh treatment, ients are ely to develop the syp&om!. ft s9s wd syn#{231}lome of loratve dyeloneela oppeer lo a patlent on RlSPERDAL , doug dlecontinuation should be However, some patents may requtre treatment wIth RISPERDAL’deepllethe preeenon of the syndrome. Potential for Proarrhythmlc Effects: Risperidone and/or 9.hydroxy. rlepeddone appears to lenhen the 01 tmeivel to enom patlerd eltho4 there to no avere iieaea to treated patler* even at 12-16 mday, mel elme the recommended does. Other drugs that prolong the 01 litervel have been aseoci. Med wIth the occurrenon of etudes de polnts a hte.threateningarrhythmia Bm bnbalwice, ooncomtlwrt use mith ar drugs that p long 01, or the presenon of congenitatprolongationto 01 cen rncreasethe dab loroccurrence of thisarrhythmia Orfho.tadc insdan: RISPERDAL may loduce orthostattr hynolension associated with rtlzziness, tachycarctla, and m some patients, syncope, especially rhihng the Mel deee.btratlon perio probably reflecting to &pha.adrenerglo wtstlo pro. The dab of odhoetatlohvpotensionend syncope may be minimized by totting the betel dose to 1 mo thb to normal acbdts arid 0.5 mg BO to the elderly and patents wWi renal ohepatlo bopeinnent (See DOSAGE AND ADMINISThATIQN). A dose redriction shorid be considered ll hypolenslon occu RISPERDAL should be used dath pardcutar caubon to patients with known carditovascular ditseese (hietmy of myocarolalbdaidtlonor iacheml trend taljre, or condriction abnormalltlee), cerebrovascular dleease, and conditions which would predispose petleritsto hypotenslon(dehy&ation, hypovolemi end tresbnentwth amihonerlenshe medlowions). Selans: RISPEROALC be used caitiousty to patients with a tdsloiy of Iy*jwulecabremia As atm other drugs that entagonize dopemtoe 0, recapto( elevates proleoth levels and the elevation persiats dadng cirronto administration. Tissue culture experiments todicale that approximately one third of hooverbreastcascara are prolecdadependent to vitro, a factor of pollenhal tropottance it the preecrrtlon of these drugs le coritensylaled to a patient with previously detected breast cancer. As is common with compounds which kicrease prohmto release, an tocreese to pitultreywr mammrey end pencreatic lobe cell hyperplasia endfor neoplasiawas observed to the Isperidone carcinogenicity studi conducted to mice and rats (See CARCtP4OGENESIS). However, neither clinical studies nor epidemiologic studies conrhicted to date have shown en association between chronic athninistrabon of the class of drugs and Wmodeneele to tunw the avalable evidence a considered too Nmitedto be concluerveat thistime. jn coqualv. aidMo hiiituient Somnolence was a commonly reported and dOee.related adverse event associated with RtSPERDAL’treatmint. Shins RISPERDAL has the potential to vnparr iudqurent, thlnldng, or motor sioll patiente shoofd be cadioned abord operating hazardous mechiorey, aAomoblle onalltheywecaflatothatRlSPERDk#{149}therspy does not alterdthem adversely. Rarecases of prm have been mporte A single case of lIP was reported a 28-year.old female patient receiving RISPERDALTh relationshto RISPERDAL therapy is imimoren. Rieperidone has en aitlematic elect to enimals this elleci may also coot to human and may mask slew and synitoms of oventoeage withcertaindrugsor of conathonssuch as toteelinalobstruction,ReyO syndrome,end brwhtumor. CaLdion is advised when ecrtlng for patients who will be expoeed toteiquer. The ooeelbllltv of asuicldsatteropt is inherent to echeophrerda and dose squervision of hig#{241} risk patients should accorreranydrug therapy. Prescr$,llons for RISPERDAL’shOUId be wrItten forthe smalleet quantity oftablets coneisteniwith good patient management, to orderto reducethe rbeOlOVerdOee. Ollnical experience with RISPERDAL’ to patientswithcerteinconcomilawi aye testis iaeaee is toilet Catitlon is advisable to patientswith Iseasee orcondevon that owed eflect metabolism or hemodynarnic meponsea Because of the rieks of orthoetatic hypotension end 01 prolongator caraton shorid be observed to cardiac patlento (See WARNINGS end PRECAUTIONS). In patients with severe renal kr#{231}airmenl (creathrine clearance <30 mLknl&1.13 is#{176}), orwith severe hepatlo tonerit, a towerstarting dose should be uset Patients should be advised ci the risk of oithoetahchypotension,especially diiimg theed of initialdose titration. Patients should be cautioned about operating hazardous machinery, todudtog automoblle seat they are reasonably certain that SPERDAL therapy does not elect them adversely. Tell patients to nasty drab plrysicien it they become pregnant or intend to become pregnant durIng therap not to breast feed an itsient to tofomr their phis it they are taldn or plea to tabe, any prescr, floe or over-the.counterdrug to avoid alcohol. No specific hmoratoryteats are recommendet The ivteractions of RISPERDAL and other drugs have not been systematically evaluated. Caiduon strand be used when taken to combination with othercerfral acitngdmgsendalcohcd. RISPERDAL’may enfsecathe hysolensive ellecisofdeartheispeislcagentewith ftdopolerdial arid itmayaritaponicethe ettectsofisvodopaanddcpenrtoeagordsta chronic administration of cwhamazepine- or clozapise with risperidone may mcrease theclearance of risperidone. Riaperidone is metabolized by cytoctwome PseIID an enzynre thatcan be tohibfed r a variety of psychotropicand other drugs. Analysis of clinical studies involving a modest numnber of poor metabolizers (niD) does not suggest that poor and eotensive metabolizershave dIfferent rates of adverse effeols No cornS parson of effectiveness to the two groups has been made. In vitrostudies showed that drugs metabolized by other es iaozymes are only weak tohthliors of deperidonemetabolism. In vitro studies indicate that risperldone is a relatively weak inhibitor of cytochiome PIID and is not expected to substantially tohbt the clearance of drugs that are metabolized by this enzymatic pathway. However, clinical data to combo this on am not avaffalile. Carcinogenicity studies were conducted to Swiss albino mice and Wistar rats Risperickine was administered tothe dietat doses of O, 5, and 10 mglkgfor l8mordhstomiceandfor25morfhstorata TheeedoeesamequlvalenttoZ4, 9.4 arid 37.5 lenes the madmum human dose (16 mgfday)on a mgfogbasis or 02, 0.75 and 3 daresthe maidmumteimen dose (mice) or 04, 1. and 6 times the maidmum human does (rats) on a mglm2 basis. There were statistically alp reticent increases to pituitary adenomas, endocrine pancreas adenomas and manimary adenocarclnom These neoplaams are considered to be ptolactln.mediatet The relevance for human risk of the findings of prolactln. medIated endocrinetumors in rodents is unknown. No esidence of mifagenic polentlal for risperldone was loud Risperidone (0.16 to 5 mofig) was shown to bopairmatIn but not fertility,to easter rats to three reproduobvestudies at doses 0.1 to 3 tInes the maidmum recommended human does on a mm2 basis. The effect appeared to be in females a aidchronlc study to Beaa dogs, sperm motilityand concentration were decreased at obese 0.6 to 10 flares the human dose on a rngfrol basis Dose-related decmasee were also noted In serum testosterone at the same doses. Serum testosterone and sperm parameters partially recovered but remained decreased after treatment was discontinued No on-Sleet doses were riolad to eitherratordo Pregeency Cataaory C: The teratogenic potential of riapeildone was studied to Sprague.Dawley enciWistar rate end to New Zealand rabbits The incIdenceof mallomiatlons was net increased con#{231}amd to control to offspring of rate or rab bits ven 0.4 to 6 tinree the human dose on a mghnh basis to three repnoducilve strides to rats there . en increaseto popdeabreduringthe host4 days of lao talionatdoeeaO.1 to3bmeethehumandoseonamgfm’baslaftisnotknown whether these deaths were titie to a direct effect on the fetuses or piw or to effects on the dress There was no noiffecti doeefor increased rat pup mortality. in one Segment IIIstudy, therewaaan increase in wilbom ratpr#{231}e atadoae 15 times tiwthan the human doeeon a mgtrn#{176}besis. Placental transfer of dadone occurs to ratpope. Thereare no adequ and weLcontnouled studies to pregeent women. However,there was one reportof a case of aganesis of the corpus ndhosum to ge wisedeopoeed to riaparidone to utem. Thecauaal relwionahlyto RISPERDAI. therapy is imimorert RISPERDAL’ ahorid be reed turing pregnancy ontyif the potential benefit justiflesthe potential rialitothe fetus The effeclon taliorend delivery to humansis unknown it is not known whether or net riapeddone is excreted to human mflk In animal studies, dapeddone and 9.hvdnoxvrlaoerldone were excreted in breast mi$ Therefore, women receiving RISPEADAL5h0utd net breasiteet Safety and effectiveness tochildrenhave not been established. clinical studies did not include sidhcierl numbers of patients aged 65 and over todslsmiinewhetherthey reeponddlhrentlyfmmynungerpatlents in general, a tower starting dose is recommended for an elderly patient, reflecting a decreased noaooldnetIc clearance to the elderly, as well as a greater fre ciency of decreased hspatic, ren or cardiac tuncdo and a greater tendency to postural hypolenaion (See WNICAI. PHARMACOLOGY and DOSAGE AND ADMINISTRA Msoclatad reith DIscontinuatIon OlTisatsessit *4ma5ely 9% psrcard(244Pa17) of RISPERDAL’treated patlenta to phase 2-3 studies discontinued treatment due to an adverse event, conspired with about 7% on placebo and 10% on active control drugs. The more common avails ( O3%)asaociated with discontinuation and considered to be poasthty or dm odet aidrepysamide sytom dunee hypadane re somnolence, and nausea Sricithal5wseaseociated*discor*uuimr to 12%of RISPERDAL4eatad patients compared to 0.6% of placebo patients, brti given the almost 40.fold iseater erqoeum tow to RISPERiAL#{149}compamd to placebo paterd I is wfkaly thatauicideatheir#{231}tisaRlSPERiAL’islatedaiMrseevei1(See PRECAUTIONS). kicidenos lii COIfIOIhdTrIalS IIa,wevsdAdveree Et*ife hr r*md ON*ef Tl Intwo 6. to 8-weak placebocoilrolsd trIal spontaneoualy.reporIe treatmer*emergant adverse events with an incidence of 5% or greater in at least one of the RISPERDAL’ gnOI4lS and at least twice that of placebo were: anidety, semen. :=r &rnwnL on, nause Etched adverse evertis toone oftheaetwotriala present at at least 5% andtwice the rate of bo were: increased dream activity, increased duration of sleep, aocommodaton datuibenca reduced ndlvatlor mictuditon diatuthence dis the walf gal men diminished mmmi deire, wecate dystu patients, butwere seen in patients recewing haloparidol (3/126). Other Events Observed DurIng the Pre-Mark.tlng Evaluation of RISPERDAL#{149} Durin9 its premsrketlng assessment, multiple doses of RISPERDAL’ were administered to 27 patients to phase 2 and 3 studies and the following sean. dons were reported: (Note ‘trequenr are those occurring in at least 1/100 pients, ‘k*equenf’ we those occurring to 1/100 to 1/1000 patIents, rwe are thoes occurring to fewer than 1/1000 patients. ft is toiportwrt to emphasize that, allhouphtheevents repoitedoccurred duringfreatmeniwith RiSPERDAL, they were not necesaariy caused by L Paynhiafifc .er#{224}rec Frequent increased dream actMty, diminished sexual daalre, nervousness. Infrequent bnpalred de apathy, increased Rado, amneelt Rare: ernotloiwi lebdity, rfgfdmares, daltmm withdrawal syndrome, yawning. Central and Peripheral Nervous System Disorders: Frequent kicreased sleep dimition’. infrequent dywth vent absy pemeatheei Outro-Intulinal Disorders: Frequent: anorexia, reduced salivation’. M_ flatulence, diwth.s, ased ep etomattes, malens, gla, hemOrrhOids, gaatrttis. Rare: focal Incontinence, eructation, gastroesc re& tholelthbai tongue edema, diverticulitia, gingivitis, dIscOlOred feces, GI hemorrhage, hematemeals. Body as a WholWOeneral Dlaorderi: Frequent: fatigue. Infrequent edema, rigors, malaise, inftuenza.Iike ymphm. Raric pallor, - - * seom bu Ddeor* in hyon, bronchospasm, atridor. Rare: asthma, increased sputum, aspiration. Skin and Ofaoi*: Frequent increased pigmentation’, photoeenslthoty’. nfmqu.nt harassed oweOl score, decreased oweab alopecis, hynedreratods, pru his, dun e,ddtaliort Rarabulous en4stor dun udosration, aggravated paodaals, turunculosis, vernuca, dermatitis lichenold, hypertrichosis, genital pnurltua, urticarla arthoneouder Dfeordsrs: Infrequent: palptiation, hypertension, hypotenalon, AVbtOck, rnyocardialkdatttuon. Ram:venthniartwirycardia, wt. his pectoris, premature sInai contractions, T wave Inversions, ventricular extraes, STdep myocardife. Vcnorderac Wseqismeabnon malemommodatuoialmia Ranccdopls,eyepals, hiepharllls,phctop. als, photophobis, abnomial lacrimation. Ra and M*lionef ordeno in_ _is, creatine phosphoNoase increase, thk wef decrease, diabetse meflk Rererdeomased sense im cachexis, - in_ to_ he dysoda Rear urinary retention, cystftia, renal Insufficiency. Muaculo-akeletal System Odeerrs in a Rear wthme hmsths, wths, SkIIetsl pain. ReproductIve Disorders, Female: Frequent menorrhagis’, or_ on’, dry vagina’. Th*wurent nonpuerperal lactetlon, amenorrhos, female breast pa belorthes, mawitis, dysmenonhes, female pedneal pals, hmnnenstmal buedina vadnal hemorrhage. UaWandRa,y System h*equert increased SOOT, increased SGPT. Rare: hepatic falhire, choicetatic he th thoWithhms, henab daav ass anJaowitoieer*r& inhquentepimaxis, puxpia Rere: hemorrhage, aupedlcim phlebitis, thrombophiebats, thrombocytopenla Rearing and Vesflbuiar D#aors: Rare: tlnnitus, hyperacusis, decreased headn OdCmbFL Th*equent anemj hyothnomic imma Rear normocytic anemia Rspreducthw somb flk ftequentr erecate dysfunction’. Infrequent: ejaculation failure. White Call and Resistance DIsorders: Rare: leukocytosis, tymphadenopathy, leucopeoda, Pelger.Huet anomaly. Endecodm savdvac Rear synecomastis, male hmaat uredo homronedisorder. wnadSenNec Raarhitlertaata ‘ incidence baaedon etched reports PbeabWothsc Adverse events reported since madad intro. duction which were temporally (but not necessarily causally) related to RISPERDAL#{149} therapy, Include the following: anaphylactic reaction, an sinS Raation, cembrovascuho diseess, diabetas molten aggravated, hypothermia, Intestinal obstruction, jaundice, mania, Paddnaon’s disease aggravated, putmonary embolism, sudden death. ABAtloEFENDcE ccsifroflid Sishstanc. Sass: RISPERDAL’is not a controlled substance. Patients should be evaluated carefully for a history of druq,abuse and such _lda alholdd be observed closely for ai9ns of RISPERDAL misuse or abuse -‘. Ltesadhi RISPERDAL’(rlspeddone)ahould be administered on a BID achedi* gener$ybSgInnIngwIIh 1 rag BID initially,with increases inincrementa ofl mpBIDonthesecoretwetterddey,estmeratedMatargatdoeeof3mg BID by the third day. In some patients, slower titration may be medically The following adverse events occurred at an tocidance of 1% or more, and were appropriate. FUrtherdOsagea4ustments, tindicata ahorid generally occurat at least as frequent 1001W RISPERDAL4TeaIed patlente treated at doses of intervais of not less than 1 wee since steady state for the active metabolite 10 mgfday then bong botreated patients to the pooled results oftwo 6. to would not be achieved for approximately I week in the typical patient. When 8-week controlled hith. Paychl*Ic Oleorderer insomnia, agitation, anxiety, dosage 4ustments are necessary, small dose increments/decrements of I rag eo reashe se Nemoun *ac aidiopyTaoldaleyswlonw’, BID are recommended. Mtloahoficefffcacywasdemonetrated toadoee ranaeof4to lemg/daytothe deneea *ao conenkon, mewn al vomlitoabdonmnalpalraMtoothactre. Raspisiorysyatamo clinicaltrials atqiportmg effectiveness of RISPERDAL however, maximal effect nitoiti cou* alnual dyspnea Body as aWholai beck pain, was generally seen to a range of 4 to 6 mg/day. Doses above6 mgkiaywere not cheat palaver. Ds,miolof$cal rash dry skin, sebonhet Wectlonai u#{231}perdemonstrated to be more efficacious than lower doses, were associated with respiratory. Visual: abnormal vision. Nuaculo.$kslital: arthralgia. more eithapy,arnidal symptoms and other adverse effects, and we not generally ovascelar.taa recommended. The safely of doses above 16 mg/day has not been evakiated to I Includes tremor, dystonia, hypokinesia, hypertonia, hyperkinesia, ocuto. clinical trials 001* hr SpecteIipsdedemo The recommended filial dose is gyric crisis, ataxia, abnormal gait, involuntary muscle contractions, 0.5 m9 BID to patients who are elderly ordeblfftate patientswlth eavere renal or hyporeflexia, and extrapyramidal disorders. Although the Incidence of knnt, andeitheriaposedtohyon orforwhom ‘extrapyramidal synsytoms does not appear to differ for the ‘ 10 mgIdaV hyjiotenalon worM pose a risk. Dosage increases to these patientsshonidbe to BID. increasastodosagesabove 1.5mgBlD eons and placebo, the data for individual dose groups in fixed dose triala incrementsofno morethano.5mg shoutd generally occur at intervals of at least 1 week In some patients, slower responae relationship (See OOSb DEPENDENCY OF titrabon may be medically appropriate. DowaDspaIdenqOlAthWWEvVIfe Datatrom twofuxed dosebsis provided Elderly or debilitated patients, andjwhents with renal bnpalnnent may have less evidence of doaerelatedness for extrepyramidal symptoms associated with ability to eliminate RISPERDAL than normal aduits. Patients with impaired done treaboert Adverse event data elicited by a cheddist for side effects hepatic function may have increases in the free fraction of the risperidone, from a large study conng 5 thred doses of RISPERDAL(1, 4, IZ and 16 bly resulting in an enhanced effect (See CLINICAl. PHARMAGOLOGY) mgklay) revealed a positive trend for the following adverse everfic sleepiness, Patientswithapredispoeltlonto hypotensive reactionsortorwhomsuch reactions horeased duration cJ sleep, accommodation distuibences, orthostatic dizziness, would pose a particular risk likewise need to be tended cautiouslyand carefrily monitored(See PRECAUTIONS). Sre*hksgfrom O1IWAMreysIhO&scThem are no systematically collected data to specifically address switching from other viOl sI asenias: RISPERDAI. is associated with orthoatatic hypolisnsion antipsychotics to RISPERDAL, or concerning concomitant administration with and tachycamia (See PRECAUTIONS). other antipsychotics. While immediate discontinuation of the previous lenpmoThe proportions of RISPERDAL’ and placebo4eated patients antipsychotic treatment maybe acceptable for some patients, more gradual meOlngawalodtedonof7%ofbudyweldwemcoropatedtoapodof discontinuation may be moat appropriate forother patients. In all cases, the period of overlapping antlysychodo administration should be minimized. When 6. to8-wealuplacebo.corfmladtrlals, revealingaafatistlcalty algellicaritty greater ofwe sin or PERDAL (18%) compared to pheebo (9% switching patients from depot antipsychotics, f medically appropriate, initIate Labomtmy asengas: A between grcr#{231} comparIson for 6. to 8-week RISPERDAL’ therapy in place of the next scheduled injection.The need for cordinuin9exiMto9jSmedIcationahoutdbereevaluatedPedodoal. controlled trials resealed no statistically signilicarit RISPERDAL4IIaCSbO differencee in the propodions of patients experiencing potentially toqxxtwd changes to routine serum chemistry, hematology, or urinalysis parameters Simliady, there Augnd 199 Deember 1004 were no RISPERDAL’Ij,lacebo dIfferences in the incidence of discominuatlons for change in serum chemistry, hematology, or urinalysis. However, JANSSEN ..==i.. RiSPERDAI. administration was associated with increases to serum prolactin (See PRECAUTIONS). TITUSVILLE, NJ 08560 ECO Changs: The electrocardiograms of 8 ouf of 380 patients taking RISPERDAL whose baseline OTc interval was less than 450 maec were observed to have QTc intervals greater than 450 isaac during treshnent (see May1995 Printed in USA WARNINGS Ohanges of this type were not seen among about 120 placebo Because a whole person is waiting to emerge. Although the exact mechanism of action is unknown: #{149} Improvement of negative symptoms and lessened risk of EPS are thought to result from blockade of serotonin 5-HT2receptors, possibly through a modulatory effect on dopamine D2 activity in the frontal cortex and the basal ganglia.* #{149} Improvement of positive symptoms is thought to result from blockade of dopamine D2 receptors in the limbic system* Dopaminergic L Lacombe S. Pharmacological *Ereshefsky nsperidone. Can iPsychiatry. 1993;38(Suppl JANSN Pharmaceutica Inc. 1995 #{149} Serotoninergic profile of 3):580-588. ‘RISPERIDONE Please see the bnef summary of Prescribing Information adjacent to this ad. ©Janssen system JPI-RS-123D Sm,thKu,na rrurou Becham A first choice in psychosis. system - ii ,4;f VENLAFAX/NE HCI A Serotonin and Norepinephrine Reuptake Inhibitor “Investigations of the action mechanisms of antidepressants have provided support for the importance of(serotonin and norepinephrinej interactions in the patho physiology of depression.” -reported Pharmacologic Compound NE TCAs2-3 ,‘ = The Histaminergic Adrenergic strong affinity. clinical reuptake #{149} Like # IbIl norepinephrine; *Serotonin Muscarinic Affinities ‘S EFFEXOR5 = Receptor 5HT SSRIs4 NE activity Inhibition Uptake in Kalus et al 5HT significance inhibition SSRIs #{149} As with = tricyclic among SSRI antidepressant; of these in vitro data varies and TCAs, SSRIs, TCA serotonin; = = selective serotonin reuptake inhibitor. is unknown. TCAs. EFFEXOR anticholinergic-like is a weak inhibitor side effects #{149} EFFEXOR is a structurally novel antidepressant, to any other available antidepressant5 may of dopamine occur and with is chemically reuptake EFFEXOR unrelated EXPAND YOUR TREATMENT POSSIBILITIES An effective firstIine depressed therapy for patients Response in depressed outpatients’ 100% #{149}EFFEXOR n39 . o75%.2 Imipramine n U Placebo a n = 33 47 0.2 co: 50%- U 25%C U 0% Baseline I 2 3 Time No significant Significant *Response 2 (much difference between 4 6 (weeks) EFFEXOR and imipramine was observed. difference (P < 0.05); venlafaxine and imipramine > placebo at week 6. to treatment was defined as CGI improvement score of I (very much improved) or improved). In one randomized, on venlafaxine double-blind, or imipramine placebo-controlled study of depressed at 75 mg to 225 mg daily in divided The effectiveness of EFFEXOR in long-term cally evaluated in controlled trials. patients doses (observed use (>6 weeks) initiated/maintained cases at week 6).’ has not been systemati- EFFEXOR is contraindicated in patients tsking monoamine oxidase inhibitors (MAOIs). EFFEXOR should not be used in combination with an MAOI or within at Iest 14 days of discontinuing treatment with an MAOI because of potential for serious adverse reactions. Based on the half-life of EFFEXOR, at least 7 days should be allOWed after stopping EFFEXOR before starting an MAOI. Treatment with EFFEXOR is associated with sustained increases in blood pressure (BP) in some patients. These appear to be dose dependent and were seen at an incidence of >5% at dosages above 200 mg/day. Regular monitoring of BP is recommended. As with any psychotropic drug, EFFEXOR may impair judgment, thinking, or motor skills, and patients should be advised to exercise caution until they have adapted The most common adverse events reported in EFFEXOR placebo) were: nausea, somnolence, dry mouth, dizziness, abnormal ejaculation/orgasm, and anorexia.5 Please see brief summary of prescribing information to therapy. clinical trials (incidence > I 0% and 2x that of constipation, nervousness, sweating, asthenia, on last page of this advertisement. HCI VENLAFAX/NE 25 Adverse Events Occurring atan Incidence of 1% or More Among Effexor-Treated Patients:The following occurred in 4- to 8- week placebo-controlled trials, with doses of 75 to 375 mg/day, at a frequency of 1% or more. This includes patients with at least one episode ofan eventat some time during treatment. Body as a Whole: headache, asthenia, infection, chills, chest pain, trauma, Cardiovascular: vasodllatation, increased blood pressure/ hypertension, tachycardia, postural hypotension. Dermatologlcal: sweating, rash, pruritus. GastroIntestInal: nausea, constipatIon, anorexia, diarrhea, vomiting, dyspepsia, flatulence. MetabolIc: weight loss. Nervous System: somnolence, dry mouth, dizziness, insomnia, nervousness, anxiety, tremor, abnormal dreams, hypertonia, paresthesia, libido decreased, agitation, confusion, thinking abnormal, depersonalization, depression, urinary retention, twitching. Respiration: yawn. SpecIal Senses: blurred vision, taste perversion, tinnitus, mydriasis. Urogenital System: abnormal ejaculation/orgasm, impo- mg, 37.5 mg, SO mg, 75 mg, and 100 mg Brief Summary See package Insert for full prescribing Information. ClInIcal Pharmacolouy: The antidepressant action of venlafaxine is believed to be associated with potentiation of neurotransmitter activity in the CNS. In preclinical studies, venlafaxine and its active metabolite, 0-desmethylvenlafaxine (ODV), were potent inhibitors of neuronal serotonin and norepinephnne reuptake and weak inhibitors of dopamine reuptake.Venlafaxine and ODV have no significant affinity for muscarinic, histaminergic, or a-i adrenergic receptors in vitro. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular eftects seen with other psychotropic drugs. Venlafaxine and ODV do not possess monoamine oxidase (MAO) inhibitory activity. Indications and Usage: Effexor is indicated for the treatment of depression. Contrslndlcatlons: Contraindicated in patients with known hypersensitivity. Concomitant use in Datients takina monoamine oxidase inhibitors (MAOIs) is contraindicated (see “WarnIngs”). Warnings: POTENTIAL FOR INTERACTIONWITH MONOAMINE OXIDASE INHIBITORS (MAOIs)Adverse reactions, some serIous, have been reported when venlafazlne therapy is inItIated soon after dIscontInuation of an MAOI and when an 00*01 Is InItiated soon after dIscontInuetion of venlafaxine. Reactions have included tremor, myoclonus, dlaphoresis, nausea, vomlt#{149} ing, flushIng, dIzzIness, hyperthermla wIth features resemblIng neuroleptic malIgnant syndrome, seizures, and death. Given these reactions as well as the serious, sometimes fatal Interactions reported wIth concomItant or immediately consecutIve admInIstratIon of MAOIs and other antidepressants with pharmacological propertIes simIlar to Eftezor, do not use Eftexorin combination wIth an MAOIor wIthIn at least 14 days of discontInuIng 00*01 treatment. Allow at least 7 days after stoppIng Effexor before starting an MAOI. Hyperthermia, rigidity, myoclonus, autonomic instabIlIty, mental status changes including extreme agItatIon progreasing to delIrIum and coma, and features resemblIng neuroleptic malignant syndrome have been reported wIth concomItant selective serotonln reuptake lnhlbltorIMAOl therapy. Severe hyperthermla and seizures, sometimes fatal, have been reported with concomitant trlcycllc antldepreuants/MAOI therapy. SUSTAINED HYPERTENSION-Effexor treatment is associated with dose-related sustained increases in supine diastolic blood pressure. Regular monitoring of blood pressure is recommended, and, when appropriate, consider dose reduction or discontinuation. PrecautIons: GENERAL-Anxiety and Insomnia: Anxiety, nervousness, and insomnia have been reported in short-term studies. Changes in Appetite.’Weight: Anorexia has been reported in short-term studies, and a dose-depen- dent weight loss has been reported in patients takinQ Effexor for several weeks. Activation of Mania,/Hypomania: Hypomania or mania has been reported; as with all antidepressants, use cautiously in patients with a history of mania. Seizures: Seizures were reported in premarketing testing (0.26%). Use cautiously in patients with a history of seizures. Discontinue it in any patient who develops seizures. Suicide: The possibility of suicide attempt is inherent in depression and may persist until significant remission occurs. Closely supervise high-risk patients during initial drug therapy. Write Eftexor prescriptions for the smallest quantity consistent with good patient managementto reduce risk of overdose. Use in Patients with Concomitant Illness: Clinical experience with Eftexor in patients with concomitant systemic illness is limited. Use cautiously in patients with diseases or conditions that could affect metabolism or hemodynamic responses. In patients with renal impairment (GFR=1O7OmL/min) or liver cirrhosis, clearance of venlafaxine and its active metabolite were decreased, resulting in prolonged elimination half-lives. A lower dose may be necessary: use with caution in such patients. INFORMATIONFORPATIENTS-Clinical studies revealedno clinicallysignificantimpairment of psychomotor, cognitive, or complex behavior performance. However, caution patients about operating hazardous machinery, including automobiles, until they are reasonably sure that Effexor does not adversely affect their ability to engage in such activities. Tell patients to 1 ) notify their physicianif they become pregnantor intendto become pregnantduring therapy,or if they are nursing;2) inform physicians about other medications they are taking or plan to take; 3) avoid alcohol while taking Effexor; 4) notify their physicians if they develop a rash, hives, or related allergic phenomena. DRUG INTERACTIONS-Cimetidine: Use caution when administering Effexor with cimetidine to patients with pre-existing hypertension or hepatic dysfunction, and the elderly. Drugs Inhibiting Cytochrome PIID6 Metabolism: In vitro, venlafaxine is metabolized to its active metabolite, 0-desmethylvenlafaxine (ODV), via cytochrome P4,IID,. Therefore drugs inhibiting this isoenzyme could potentially increase plasma concentrations of venlafaxine and decrease concentrations of ODV. Drugs Metabolized by Cytochrome PIID,: In vitro, venlafaxine is a relatively weak inhibitor of this isoenzyme; clinical significance is unknown. Monoamine Dxidase Inhibitors: See “Contralndlcations and Warnings. CNS-Active Drugs: Use of venlafaxine with CNS-active drugs has not been systematically evaluated; therefore, use caution when administering Effexor with such drugs. CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITV-Carcinogenesis: In 18-month studies, there was no evidence of carcinogenicity in mice given 120mg/kg/day [16 times the maximum recommended human dose (MRHD)J. In 24-month studies, there was no evidence of carcinogenicity in rats given 120mg/kg/day. Mutagenicity: In male rats receiving 200 times (on a mg/kq basis) the MRHD, chromosomal aberrations were found in the bone marrow in vivo. Impairment ofFertility: No impaired reproductivefunction was found in rats given 8 times (mg/kg) the MRHD. PREGNANCY-Teratogenic Effects-Pregnancy Category C. Reproduction studies in rats given 11 times, and rabbits given 12 times the MRHD (on a mg/kg basis) revealed no malformations of offspring. However, in rats given 10 times the MRHD, there was a decrease in pup weight, increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation when dosing began during pregnancy and continued until weaning. There are no adequate and well-controlled studies in pregnant women; use Effexor during pregnancy only if clearly needed. LABOR, DELIVERY, NURSING-The effect on labor and delivery in humans is unknown. It is also not known whether Effexor or its metabolites are excreted in human milk; exercise caution when administering to a nursing woman. PEDIATRIC USE-Safety and effectiveness in children (<18 years) have not been established. GERIATRIC USE-In clinical trials, 12% of Effexor-treatedpatients were 65 years of age. Overall differences in efficacy or safety in the elderly have not been demonstrated, however, greater sensitivity of older patients should not be ruled out. Adverse ReactIons: ASSOCIATED WITH DISCONTINUATION OF TREATMENT-Nineteen percent (537/2897) of Effexor patients in clinical trials discontinued treatment due to an adverse event. The more common events (1% associated with discontinuation and considered to be drug-related included: somnolence, insomnia, dizziness, nervousness, dry mouth, anxiety, nausea, abnormal ejaculation (male), headache, asthenia, and sweating. INCIDENCE IN CONTROLLED TRIALS-Commonly Observed Adverse Events in Controlled Clinical Trials: The most commonly observed adverse events associated with the use of Effexor incidence of 5% or greater and incidence for Effexor at least twice that for placebo): asthenia tence, urinary frequency, urination impaired, orgasm disturbance, menstrual disorder. Studies indicate a dose dependency for some ofthe more common adverse events associated with Effexor use. There also was evidence of adaptation to some adverse events with continued Effexor therapy over a 6-week period. Vital Sign Changes: In clinical trials, Effexor was associated with a mean increase in pulse rate of about 3 beats/mm, and a dose-dependent increase in mean diastolic blood pressure of 0.7 to 2.5 mmHg. Laboratory Changes: During clinical trials, only serum cholesterol exhibited statisticallysignificant differences from placebo (increases of 3 rng/dL from baseline); clinical significance is unknown. ECG Changes: Only heart rate exhibited a statisticallysignificant difference, with mean increases of 4 beats per minute from baseline. OTHER EVENTS OBSERVED DURING THE PREMARKETING EVALUATION OF EFFEXOR-Durlng premarketing assessment, multiple doses of Effexorwere administered to 2,181 patients, and the following adverse events were reported. Note: “frequent’ = events occurring in at least 1/100 patients; Infrequent” = 1/100 to 1/1000 patients; “rare’ = less than 1/1000 patients. Events are classified within body system categories and enumerated In order of decreasing frequency using the definitions above. It is important to emphasize that although the events occurred during Effexor treatment, they were not necessarilycaused by it. Body as a Whole - Frequent accidental injury, malaise, neck pain; Infrequent: abdomen enlarped, allergic reaction, cyst, face edema, generalized edema, hangover effect, hernia, intentional injury, moniliasis, neck rigidity, overdose, chest pain substernal, pelvic pain, photosensitivity reaction, suicide attempt; Rare: appendicitis, body odor, carcinoma, cellulitis, halitosis, ulcer, withdrawal syndrome. CardIovascular system - Frequent: migraine; Infrequent: angina pectoris, extrasystoles, hypotension, peripheral vascular disorder (mainly cold feet and/or cold hands), syncope, thrombophlebitis; Rare: arrhythmia, first-degree atrioventricular block, bradycardia, bundle branch block, mitral valve disorder, mucocutaneous hemorrhage, sinus bradycardia, varicose vein. DiUestlve system - Frequent dysphagia, eructation; Infrequent colitis, tongue edema, esophagitis, gastntis, gastroententis, gingivitis, glossitls, rectal hemorrha9e, hemorrhoids, melena, stomatitis, stomach ulcer, mouth ulceration; Rare: cheilitis, cholecystitis, cholelithiasis, hematemesis, gum hemorrhage, hepatitis, ileitis, jaundice, oral moniliasis, Intestinal obstruction, proctitis, increased salivation, soft stools, tongue discoloration, esophageal ulcer, peptic ulcer syndrome. EndocrIne system - Rare: goiter, hyperthyroidism, hypothyroidism. Hemlc and lymphatic system - Frequent ecchymosis; Infrequent anemia, leukocytosis, leukopenla, lymphadenopathy, Iymphocytosis, thrombocythemia, thrombocytopenia, WBC abnormal; Rare: basophilia, cyanosis, eosinophilia, erythrocytes abnormal. MetabolIc and nutrItIonal - Frequent peripheral edema, weight gain; Infrequent alkalIne phosphatase Increased, creatlnine increased, diabetes mellitus, edema, glycosuria, hypercholesteremia, hyperglycemia, hyperlipemia, hyperuricemia, hypoglycemia, hypokalemia, SGOT increased, thirst; Rare: alcohol intolerance, bilirubinemia, BUN increased, gout, hemochromatosis, hyperkalemia, hyperphosphatemla, hypoglycemic reaction, hyponatremia, hypophosphatemia, hypoproteinemia, SGPT increased, uremia. Musculoskeletal system - Infrequent arthritis, arthrosis, bone pain, bone spurs, bursitis, joint disorder, myasthenia, tenosynovitis; Rare: osteoporosis. Nervous system - Frequent emotional lability, tnsmus, vertigo; Infrequent apathy, ataxia, circumoral paresthesia, CNS stimulation, euphoria, hallucinations, hostility, hyperesthesia, hyperkinesia,hypertonla, hypotonia, incoordination, libido increased, myoclonus, neuralgia, neuropathy, paranoid reaction, psychosis, psychotic depression, sleep disturbance, abnormal speech, stupor, torticollis; Rare: akathisia, akinesia, alcohol abuse, aphasia, bradykinesia, cerebrovascular accident, loss of consciousness, delusions, dementia, dystonia, hypokinesia, neuritis, nystagmus, reflexes increased. RespIratory system Frequent bronchitis, dyspnea; Infrequent asthma, chest congestion, epistaxis, hyperventilation, laryn9ismus, laryngitis, pneumonia, voice alteration; Rare: atelectasis, hemoptysis, hypoxia, pleurisy,pulmonary embolus, sleep apnea, sputum increased. SkIn and appendages - Infrequent acne, alopecia, brittle nails, contact dermatitis, dry skin, herpes simplex, herpes zoster, maculopapular rash, urticaria; Rare: skin atrophy, exfoliative dermatitis, fungal dermatitis, lichenoid dermatitis, hair discoloration, eczema, furunculosis, hirsutism, skin hypertrophy, leukoderma, psoriasis, pustular rash, vesiculobullous rash. SpecIal senses - Frequent abnormal vision, ear pain; Infrequent cataract, conjunctivitis, corneal lesion, diplopia, dry eyes, exophthalmos, eye pain, otitis media, parosmia, photophobia, subconjunctival hemorrhage, taste loss, visual field defect; Rare: blephantis, chromatopsia, conjunctival edema, deafness, glaucoma, hyperacusis, keratitis, labyrinthitis, miosis, papilledema, decreased pupillary reflex, sclerttis. UrogenItal system Frequent anorgasmia, dysurla, hematuria, metrorrhagia”, urination Impaired, vaginitis’; Infrequent albuminuria, amenorrhea”, kidney calculus, cystitis, leukorrhea, menorrha9la’, noctuna, bladder pain, breast pain, kidney pain, polyuna, prostatitis”, pyelonephritis, pyuna, urinary incontinence, urinary urQency, uterine fibroids enlarged”, uterine hemorrhage”, vaginal hemorrhage”, vaginal moniliasis’; Rare: abortion”, breast engorgement, breast enlargement, calcium crystalluria, female lactation”, hypomenorrhea#{176}, menopause”, prolonged erection’, uterine spasm”. (“Based on the number of male or female patients as appropriate.) Drug Abuse And Dependence: CONTROLLED SUBSTANCE CLASS-Effexor is not a controlled substance. In a retrospective survey of new events occurring during taper or following discontinuation, the followinq occurred at an incidence of5%, with incidence for Effexor at least twice that for placebo: asthenia, dizziness, headache, insomnia, nausea, and nervousness. Taper the dose gradually and monitor the patient. Evaluate patients carefully for history of drug abuse and observe such patients closely for signs of Effexor misuse or abuse (e.g. development of tolerance, incrementations of dose, drug-seeking behavior). Dosage and AdmInIstratIon: The recommended starting dose is 75mg/day In 2 or 3 divided doses, taken with food. If needed, dose increments of up to 75mg/day should be made at intervals of no less than 4 days. Maximum recommended dose, for use in severelydepressed patients, is 375mg/day, in 3 divided doses. When discontinuing Eftexor after more than 1 week of therapy, the dose should be tapered to minimize the risk of discontinuation symptoms. SWITCHING PATiENTS TO OR FROM A MONOAMINE OXIDASE INHIBITOR At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with Effexor. In addition, at least 7 days should be allowed after stopping Effexor before starting an MAOI (see “Contralndlcations’ and “Warnings’). Please consuit full prescribing information for detailed dosing instructions. This brief summary is based on CI 4193-2, issued May 23, 1994. References: 1 Kalus 0, Asnis GM, van Praag HM. The role of serotonin in depression. Psychiatric Annals. 1989;19:348-353. 2. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry. 1992;53(suppl):5-18. 3. Richelson E. Synaptic pharmacology of antidepressants: an update. McLean Hosp J. 1988;8:67-88. 4. Physicians’ Desk Reference. 48th ed. Montvale, NJ: Medical Economics Co Inc; 1994; Prozac’.877-880; Zoloft:2000-2003; PaxW”:2267-2270. 5. EFFEXOR prescribing information, Wyeth-Ayerst Laboratories, Philadelphia, PA. 6. Data on file, Wyeth-Ayerst Laboratories. 12% vs. 6%), sweating (12% vs. 3%), nausea (37% vs. 11%), constipation (15% vs. 7%), anorexia (11% vs. 2%), vomiting (6% vs. 2%), somnolence (23% vs. 9%), dry mouth (22% vs. 11%), dizziness (19% vs. 7%), nervousness (13% vs. 6%), anxiety (6% vs. 3%), tremor (5% vs. 1%), blurred vision (6% vs. 2%), abnormal ejaculation/orgasm male (12% vs. <1#{176}h), and male impotence (6#{176}!. vs. <1%). S 0 1994, Wyeth-Ayerst Laboratories 83561 WYETH-AYER& LABORATORiES August 1994 INSTITUTE 0111 PSYCHIATRIC SERVICES OCTOBER 0-ID. 1005 BOSTONMARRIOTTCOPLEYPLACE For more American information, Psychiatric CALL 202-682-6237 Association, 1400 or FAX 202-682-6345 K Street, NW, Washington, or MAIL to IPS, DC 20005. Name Facility Address City/State/Zip PS 9/95 Psychopharmacology of eating disorders Sunday B. Timothy College Walsh, of Clinical Professor of Columbia l)i rector, New York New York, Physicians MD Psychiatry & Surgeons I)isorders Research State Psychiatric Institute Un it l:IilIIl in grant (_dLLCdtiOfllI Eating York h’ Stip1orted University New October 8, 1995 6:30 -8:30 AM Grand Ballroom Salon E, 4th floor Boston Marriott Copley Place and unresrricrcd horn (:OI1I)(lI\ S1onsoicd l)v ihe i\iiericin Psvchiitric /\ssuciJtiofl ( Late-Life Depression: Recent Advances In Assessment and Treatment October Sunday, 7:00PM Grand 10:00PM Ballroom Marriott Boston Salon G Copley Plaza Registration by the American Sponsored Boxed dinner Andrew will on Site Psychiatric Association at 6.00 be available F. Leuchter, Treatment Charles M.D., ofDepression F. Reynolds, PM Chair in Late Life III, M.D. Professor of Psychiatry and Neurology MHCRC for the Study of Late-Life Mood Western Psychiatric Institute and Clinic Director, Depression - 8, 1995 in the Frail Elderly: Ira Katz Director, Section University Outcomes Cornell Brain Psychiatric-Medical M.D., Ph.D. Depression M.D. Alexopoulos, Professor of Psychiatry University Medical Imaging in Late-Life Andrew F. Leucbter, Associate Co-Morbidity on Geriatric Psychiatry of Pennsylvania ofLate-L/’e George Disorders Professor College Depression M.D. of Psychiatry Director, QEEG Laboratory Neuropsychiatric Institute University of California Los Angeles Diagnosis and Treatment ofDepression in Late L/’e: Barty D. Lebowit Ph.D. Summary and Conclusions Chief, Mental Disorders of the Aging Research Branch National Institute of Mental Health The American Supported by an unrestricted educational grant from Wyeth-Ayerst Psychiatric Association is accredited by the Accreditation Council to sponsor continuing medical education for physicians. The APA designates \.__ Physician’s Recognition this Award continuing medical of the American education Medical activity Association for 3 credit Laboratories. for Continuing hours in Category and for the CME requirement Education I of the of the APA. in Psychoses Progress ANOTHER Sponsored by the In conjunction MEETING American with Monday, Psychiatric the Institute G, Fourth At the conclusion Boston Psychiatric Understand Services. Be familiar . Review the clinical of schizophrenia; . Master hypotheses with appropriate with adverse Dopamine Treatment _ -..- --“-- 4 Columbia University in Schizophrenia Factors in Psychoses Psychobiology, Generation Therapeutics Columbia University of Antipsychotic Branch, on Positive M.D., of Psychiatry, Drugs M.D. West Medical and College Institute of Mental Health Symptoms Negative of Georgia Schizophrenia Los Angeles is supported Pharmaceutica National Ph.D. of Refractory Stephen R. Marder, Chief of Psychiatry, presentation patients. M.D. L. Bonson, Chairman for schizophrenia; schizophrenia Psychobiology, of Clinical of Drugs Richard refractory drugs; symptoms Center of Experimental Effects neuroleptic of drugs Serotonin a New Pickar, Chief in M.D. Department David serotonin and negative effects Epigenetic and Jack M. Gorman, Chief, to: M.D. Research/Psychopharmacology, VA Medical Towards be able M.D., Chairperson and Genetic side of Clinical E. Casey, Psychiatric Portland of factors use of atypical to treating approaches Department Daniel Chief, and of positive aspects Jack M. Gorman, Chief, Place should pathophysiology; . Be familiar Copley the participant of dopamine the current I Marriott presentation, Consider the neurobiology in schizophrenia; Janssen SCHIZOPHRENIA 9, 1995 Floor, of this schizophrenia’s This ON Massachusetts Salon S SERIES p.m. Boston, . A Association on October 5:15-8:15 IN VA Medical Center by an unrestricted educational grant from & Research Foundation. Association is accredited by the Accreditation The American Psychiathc Council for Continuing Medical Education sponsor continuing medical education for physicians. The APA designates this continuing medical education activity for 3 credit hours in Category 1 of the Physician’s Recognition Award of the American Medical Association and for the CME requirement of the APA. You must register for the IPS Meeting To register for the IPS Meeting, at (202) 682-6100. To register for the symposium, Ii S 9 S r SI in order to attend please call please call this symposium. the American CML, Inc. to Psychiatric at (800) 447-4474 Association or (714)250-1008. © 1995 CME, Inc. October Calendar (Continuedfrompage 866) sources International, Inc., 3202 Tower Oaks Boulevard, Rockville, Maryland 20852; 301-770-0610, fax 301-4682245. October American Adolescent 17-22, annual meeting, Academy of Child and Psychiatry, New Orleans Marriott, New Orleans. Contact Virginia Q. Anthony, Executive Director, AACAP, 36 1 5 Wisconsin Avenue, N.W., Washington, D.C. 20016; 202966-7300. 18-20, international symposium on therapeutic foster homes and psychiatry, sponsored by the International Research Association on Therapeutic Foster Homes in Psychiatry, Palais des Congr#{232}s,Vichy, France. Contact Au Abdelfattah, M.D., President, AIRAFFP, IXIA Congr#{232}s,9 rue Richan, 69004 Lyon, France; 33-78-2867-37, fx 33-87-27-98-82. October 18-21, annual meeting, Canathan Federation of Mental Health Nurses, Toronto, Ontario, Canada. Contact Pauline Smith, Department of Nursing, Clarke Institute of Psychiatry, 250 College Street, Toronto, Ontario, Canada M5T 1R8; 416-979-2221. October October 18-21, conference on cukivating treatment strategies, sponsored by the Third International Conference on Refractory Depression, Silverado Country Club and Resort, Napa Valley, California. Contact Pragmaron, 2 1 1 East Chicago Avenue, 15th Floor, Chicago, Illinois 60611. October congress 18-21, fourth on emergency international psychiatry, sponsored by the International Association for Emergency Psychiatry, Torino, Italy. Contact Professor Pier Mana Furlan, M.D., Servizio Psichiatrico Universitario, Azienda Ospedaliera San Luigi Gonzaga, 1 0043 Orbassano, Torino, Italy; 011-902-6504, flux 011902-6595, e-mail [email protected]. October 19-20, conference health, and on worn- en, mental substance abuse, sponsored by the Florida Mental Health Institute and the Florida Consumer Action Council for Mental Health, Tampa, Florida. Contact Patricia Cleveland, FMHI, University of South Florida, 13301 Bruce B. Downs Boulevard, Tampa, Florida 33612; 813974-4694, fx 813-974-4699. 890 19-22, American annual Academy meeting, of Psychiatry and the Law, Westin Hotel, Seattle. Contact Jacquelyn T. Coleman, Executive Director, AAPL, 1 Regency Drive, P.O. Box 30, Bloomfield, Connecticut 06002; 203-242-5450. October 20-24, first Latin-Amencan congress on neuropsychophanmacology, Salvador, Bahia, Brazil. Contact JZ Congressos Medicos, Run Visconde Silva, 52 conj. 505, 22271090 Rio de Janeiro, Brazil; 02 1-2862846, fltx021-226-935 1. October tional 22-24, disability ninth annual management nacon- ference, Crystal Gateway Marriott, Arlington, Virginia. Contact Sandra Lehrer, Washington Business Group on Health, 777 North Capitol Street, N.E., Suite 800, Washington, D.C. 20002; 202-408-9320, TDD 202-4089333. October scientific meeting, of Psychiatrists, Fukuoka, Japan. Contact Satoshi Tsutsumi, M.D., Secretariat for the Seventh Meeting oIPRCP, Department of Psychiatry, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonankti, Fukuoka 814-01, Japan; 81-92801-1011, ext. 3385, fax 81-92-8633150. Pacific October 24-27, Rim College 27-November 2, annual Association of of Departments of Psychiatry, Washington and Capitol Hiltons, Washington, D.C. Contact Fredcrick G. Guggenheim, M.D., SecretaryTreasurer, AACDP, University of Arkansas Medical Sciences Center, 4301 West Markham, Mail Slot 554, Little Rock, Arkansas 72205; 501-686-5483. meeting, Chairmen American October 29-November 2, annual meeting, American Public Health Association, Convention Center, San Diego. Contact Convention Services, APHA, 1015 15th Street, N.W., Washington, D.C. 20005; 202-7895670. October 29-November 3, seventh congress of the International Psychogeniatnic Association, Sheratonon-the-Park Hotel, Sydney, New South Wales, Australia. Contact Associate Professor Edmond Chiu, Department ofPsychiatry, University ofMelbourne, Mont Park Hospital Campus, Private Bag 1 , Rosanna Victoria 3084, New South Wales, Australia; 61-3-4560194, &x 61-3-458-2274. Psychiatric Services November November Group chiatry, White 2-4, semiannual meeting, of Psy- for the Advancement Stouffers Westchester Hotel, Plains, New York. Contact Allan Beigel, M.D., President, GAP, P.O. Box 28218, Dallas, Texas 75228; 214-3881310, fax 214-381-3509. November 2-5 , annual meeting, American Association for Marriage and Family Therapy, Sheraton and Hyatt Hotels, Baltimore. Contact Michad Bowers, Executive Director, AAMFF, 1 100 17th Stteet,N.W., 10th Floor, Washington, D.C. 20036; 202452-0109, &x 202-223-2329. November 9-1 1, annual conference, Association for Medical Education and Research in Substance Abuse, Sheraton City Centre Hotel, Washington, D.C. Contact Phyllis Arnold, AMERSA, Brown University, Box G-BH, Providence, Rhode Island 02912; 401-863-7791, email [email protected]. November 9-12, annual meeting, Academy of Psychosomatic Medicine, Princess Marquis Hotel, Palm Springs, California. Contact Evelyne Halberg, 5824 North Magnolia, Chicago, Illinois 60660; 312-784-2025. November 12-14, conference on innovations in trauma rehabilitation, sponsored by Bethesda Hospital and the Transport Accident Commission, Hilton on the Park Hotel, Melbourne, Victoria, Australia. Contact DC Conferences, P.O. Box 629, Willoughby, New South Wales 2068, Australia; 61-2-4396744, fax 61-2-439-2504. December December 1-3 , annual meeting, American Academy of Psychiatrists in Alcoholism and Addictions, Ritz Carlton Hotel, Amelia Island, Florida. Contact Jeanne G. Trumble, MS.W., Executive Director, AAPAA, 8340 Mission Rosd, Suite 66206; B-4, Prairie Village, Kansas 913-341-6680, fax 913-642-2431. 1 1-1 5, annual meeting, American College of Neuropsychopharmacology, Caribe Hilton, San Juan, Puerto Rico. Contact Oaklye Ray, Ph.D., Secretary, AN, Vanderbilt University, 1823 Station B, Nashville, TenDecember nessee 37235; 615-327-7200, fx 615- 327-7078. September 1995 Vol. 46 No.9 0 CD: A DECADE SATURDAY, Marriott, CHAIRPERSON: Eric PRESENTERS: Michael The Psychiatric Aiiicrican Education APA Recognition to sp11sor clesigililtcs AsvaI(l Association contiluhilig this of continuing the (APA) G, 4th A.Jenike, the M.D., is accredited h)i nedical cducation American \icdical Assocation Supported l)\ an tticstrictcd Floor Lewis M.D.,John American edticatioii Place M.D. Zohar, k I11C(liCdl Salon Hollander, 1995 A.M. Copley Ballroom, Joseph The - 8:30 A.M. Boston S/)OflSO?’Pd 7, OCTOBER 6:30 Grand OF PROGRESS H. Greist, Psychiatric b’ the R. Baxter, M.D. Association. ( ACCrC(litatioll ouncil for activity and I for for the c(lUcati()Ilal credit IU)LLI5 (\IE rcqtiirciciit giaiit froni in 1 (atcgorv of the the Physician’s Inc. CoCenss The Essential the Dually Element of \PA. Collaboration: National (Mental Conference Association Diagnosed Illness/Mental 29 November Radisson and . \Ie(liCdl Ccuitinuiiig physicians. 12th Annual - M.D. - Twin Retardation) 2 December Towers Convention Hotel Center, . Orlando, Florida For a Conference and/or call Brochure an Exhibitor or fax Management Excellence Phone: Inc. 513.223.8008 Fax: 513.223.6307 for Prospectus, 1995 New Frontiers in Psychiatric Treatment and Managed Care . INSTITUTE 11111 . . PSYCHIATRIC SERVICES OCTOBER 0-ID. 1005 . . E#{149}:Jl iISJI Over 120 Sessions 13 Blockbuster Courses 42 Hours of CME Available Discounts for Registration by September 1, 1995 8 Industry-supported Symposia Including Breakfast, Lunch and Evening Symposia some of the key faculty scheduled to present Marshal F. Folstein, M.D. Steven M. Mirin, M.D. Marshall Forstein, M.D. Robert T. M. Phillips, M.D., Renato D. Alarcon, M.D. Shervert H. Frazier, M.D. Anne Alonso, Ph.D. Jack M.Gorman,M.D. .. Ph.D. #{149}ADOLESCENT AND CHILD PSYCHIATRY Ezra E. H. Griff ith, M.D. Leona L. Bachrach, Ph.D. Thomas G. Gutheil, M.D. Carolyn B. Robinowitz, M.D. #{149}APA PRACTICE GUIDELINES Jerrold F. Rosenbaum, M.D. #{149}CROSS-CULTURAL ISSUES #{149}DEPRESSION James E. Sabin, M.D. Robert E. Hales, M.D. . Carl C. Bell, M.D. Leston L. Havens, M.D. Thomas E. Brown, Ph.D. Marvin I. Herz, M.D. Joseph T. Coyle, M.D. Eric Hollander, M.D. Leah J. Dickstein, M.D. Douglas G. Jacobs, M.D. Harold I. Eist, M.D. Michael A. Jenike, M.D. Mary Jane England, M.D. #{149}ADMIN1STRATIVE PSYCHIATRY Charles W. Popper, M.D. Paul S. Appelbaum, M.D. Allan Beigel, M.D. . . some ofthe featured sessions DSM-IV Melvin Sabshin, M.D. #{149}DUAL DIAGNOSIS Carl Saizman, M.D. . ECT #{149}EMERGENCY PSYCHIATRY Steven S. Sharfstein, M.D. John S. Mcintyre, M.D. Max Fink, M.D. Robert Micheis, M.D. Michael B. First, M.D. Sheldon I. Miller, M.D. #{149}GERIATRIC PSYCHIATRY Leonard I. Stein, M.D. Nada L. Stotiand, M.D. Jeremy A. Lazarus, M.D. Joseph T. English, M.D. #{149}FEMALE PATIENTS I HIV/AIDS . NEUROIMAGING John A. Talbott, M.D. . PSYCHOPHARMACOLOGY E. Fuller Torrey, M.D. . PSYCHOTHERAPY #{149}PTSD Ming T. Tsuang, M.D. #{149}RECOVERED MEMORY Stuart C. Yudofsky, M.D. . SCHIZOPHRENIA #{149}SUBSTANCE ABUSE Laurie M. Flynn, MA. Robert B. Miliman, M.D. r . . . - registration I I fee just $275 IName Daily advance registration I I fee only $95 I Full-time advance Psychiatric pay just $50 residents I I L - - - - . - For more information, American - - - - - - CALL (202) 682-6237 Psychiatric Association, - - - - - VIOLENCE - - or FAX (202) 682-6345 - - - 1 - or MAIL to: DC 20005. 1400 K Street, NW, Washington, I I I Facility I Address City/State/Zip I I PS9195 _ _ _ _ _ - - - - - - - - - - - - - - - - - - - - lii evoke in the therapist is in conflict with the ultimate goals of personal growth and autonomy and that the therapist’s resistance to being placed in that role is intended to best serve the patient’s wel&rc. Thus the therapist must give pnimacy to beneficence when the patient truly is unable to control selfdestructive impulses. However, when the patient engages in suicidal behavior in the interest of a regressive dependent wish to be rescued by the therapist but is actually capable of responsible action if enabled to take it,then the therapist must give primacy to autonomy. By being respectful of the patient’s autonomy, even to the point of recognizing the patient’s ultimate capacity to take his or her life (although, ofcourse, not encouraging or condoning self-destructive behavion), the therapist invites open communication about the distress that has led to the suicidal feelings. By encouraging autonomy, the therapist helps the patient work toward control ofhis or her life. Conclusions: the clinical-ethical interface The successful management of the suicidal patient thus illustrates the need for flexible dynamic application of ethical principles. Rigid adherencc to the principle of autonomy, which is currently the primary focus in ethical studies and discussions, would unnecessarily risk the lives of acutely suicidal patients. Rigid interpretation of the principle of beneficence would unnecessarily risk consigning many chronically depressed patients to lives of dependency and chronic patienthood. When the patient realizes what such therapeutic failure entails, this approach may result in the very act that it seeks to prevent-the patient’s suicide. Clearly, what is called for in the treatment of sucidal patients is not the rigid application ofethical pninciples. A philosophical alternative to such rigidity has been offered by Arras (3) andJonsen and Toulmin (17), who propose a new case-based casuistry in which the ethical principles that arc most applicable to the par- Psychiatric Services September 1995 ticular case are discovered in the clinical situation. This approach need not entail sacrificing useful bioethical principles to a philosophy of situational ethics in which “anything goes.” Rather, it calls for clinicians to be flexible in prioritizing bioethical principles that can usefully inform clinical decision making. The management of suicidal behavior illustrates the need for flexibility at the clinical-ethical interface. Aggressive measures to prevent suicide are appropriate in the management ofacutely suicidal patients and those with periodic recurring psychoses. For these patients, the ethical principle ofbeneficence guides clinical decisions. However, many patients who chronically engage in suicidal behavior are best treated more flexibly with the focus on expanding patients’ assumption of nesponsibility for their own lives. For these patients, the ethical principle of autonomy is prioritized. Preserving a dynamic clinical-ethical interface is more appropriate than rigidly applying ethical principles. References 1. and the ethics ofmedicine. Canadian ofPsychiatry 31:91-96, 1986 Journal 10. Szasz T: The tween Survival Wolman B, Gardner, 1976 1 1 . Pellegnino Psychiatric EthOxford University ED, Good: Patient’s Thomasma DC: The Restoration For the of Be- neficence inHealthCare. NewYork,OxfordUniversityPress,1988 12. Gunderson J: Borderline Personality Disorder. Psychiatric 13. Washington, Press, 1984 Hendin with reference American Journal 1150-1158, 1991 14. 15 DC, American H: Psychodynamics particular of suicide, to the young. of Psychiatry 148: Olin H: Psychotherapy of the chronically suicidal patient. American Journal ofPsychotherapy 30:570-575, 1976 . Silver D, Rosenbluth process, in Handbook orders. Edited M. New York, M: The assessment ofBorderline by Silver International D, Dis- Rosenbluth Universities Press,1992 16. Schwartz D, Flinn D, Slawson P: Treatment ofthe suicidalcharacter. American Journal of Psychotherapy 28:194-207, 1974 17. Jonsen AR, Casuistry: A ing. Berkeley, Press, 1988 Institute Bloch S, ChodoffP(eds): ics, 2nd ed. New York, ethics of suicide, in Beand Suicide. Edited by Krauss H. New York, Services Toulmin 5: The History of Moral Universityof Abuse of Reason- California on Psychiatric Set for Boston Press,1991 2. Beaucharnp ofBiomedical Childress JF: Principles Ethics, 3rd ed. New York, University Press, 1989 Oxford 3. U, Arras JD: Getting down to cases: the revival ofcasuistry in bioethics. Journal of Medical Philosophy 16:29-51, 1991 4. Beck AT, Brown G, Berchick RJ, en al: Relationship between hopelessness and ultimate suicide: a replication with psychiatric outpatients. American Journal of Psychiatry147:190-195, 1990 5. Best from dian 6. Heyd E: Suicide: ethical and moral issues a theological perspective. CanaJournal of Psychiatry 31:97-100, 1986 D, Bloch Psychiatric ChOdOfF, Press, 7. Hawnon British 5: The Ethics. P. New ethics Edited York, 1981 K: Assessment Journal ofsuicide, in by Bloch S, Oxford University of suicide of Psychiatry risk. 150:145- 153, 1987 8. Kreitman N: The clinical assessment and management of the suicidal patient, in Suicide. Edited byRoyA. Baltimore, Wilhams & Wilkins, 1986 9. Sakinofsky VoL 46 I, Swam G: Suicidal No.9 The Institute on Psychiatric Services (formerly called the Institute on Hospital and Community Psychiatry) will be held October 6-10 at the Boston Marriott Copley Place. The program includes major sessions on managed care issues, psychopharmacology, violence, substance abuse, and APA’s new practice guidelines. Thirteen CME courses will be offered. Fifteen mental-health-related organizations will meet in conjunction with the Institute. H. Richard Lamb, M.D., of Los Angeles is chairman ofthe program committee. For more information, see the preliminary institute program published in thejune 1995 issue of Psychiatric Services on contact Wanda Sheridan, Institute on Psychiatnic Services, American Psychiatric Association, 1400 K Street, N.W., Washington, D.C. 20005; telephone, 202-682-6314. patients 921 depression one found is nearly identical in our study. A majority of patients to the in our study (54 percent) and in the study by Ross and colleagues (68 percent) were diagnosed as having at least one comorbid psychiatric disorder. Haliicas and associates (16) found that 56 percent ofthe 7 1 inpatient female alcoholics they examined met lifetime criteria for an additional psychiatric diagnosis; unipolar depression (24 percent) and sociopathy (19 percent) were the most prevalent disorders. Hesselbrock and co-workers (17) cxamined current and lifetime psychopathology in 90 hospitalized female alcoholics. Depression (38 percent) and phobias (29 percent) were the most prevalent current psychiatric disorders; the lifetime prevalence of antisocial personality disorder was 20 percent. General population surveys support the association between substance dependence, personality disorders, and depression. Alcoholabusing or -dependent women in the Epidemiologic Catchment Area (ECA) study were 2 .7 and 1 2 times more likely, respectively, to receive a lifetime diagnosis of major depression or antisocial personality disonder, respectively, than women in the general population who did not have an alcohol use disorder (18). For women in the ECA study with alcohol abuse or dependence, lifetime prevalence rates were 19 percent for major depression and 1 0 percent for antisocial personality disorder. Conclusions Substance use disorders are endemic in the population of women treated in VA hospitals. Women with substance use disorders had higher rates of most psychiatric disorders and some medical disorders than women without substance use disorders. Female veterans with substance-related diagnoses had higher rates of inpatient utilization than female veterans with no substance use disorders. A majority of the women with substance use disorders who were hospitalized in the first half of fiscal year 1991 were rehospitalized by the end ofthe fiscal year. Efforts should be undertaken to Psychiatric Services September 1995 replicate these findings using standardized diagnostic procedures with other samples of women oflower socioeconomic status. Prevalence, alcoholism investigation was funded by interagency agreement RA-ND-90-37 with the financing and services research branch of the Division of Applied Research ofthe National Institute on Drug Abuse. References 5: Women, Comprehensive alcohol, Edited York, Marcel-Dekker, AlcoholAddiction. New and drugs, Handbook ofDrug 14. Vital and Health Statistics: National Hospital Discharge Survey: Annual Summary 1987. Hyattsville, Md, NationalCenter for Health Statistics, 1989 in 2. Wilsnack SC, Klassen AD, Schur BE, et al: Predicting onset and chronicity of women’s problem drinking: a fiveyear longitudinal analysis. American Journal ofPublic Health 81:305-317, 1991 3. Institute of Medicine: Broadening the Base ofTreatment for Alcohol Problems. Washington, DC, National Academy Press, 1990 Affairs, 5. Wilsnack RW, AD: Women’s Wilsnack SC, Kiassen drinking and drinking problems: patterns from a 1 98 1 national survey. American Journal of Public Health 74:1231-1238, 1984 6. Wilsnack SC, Wilsnack RW: Epidemiology of women’s drinking. Journal of SubstanceAbuseTreatment 3: 1 33-1 57, 1991 Moos Services Abuse RH, Pasch Utilization Patients CostsforFY9O. ment 8. Ross HE, Glaser FB, Germanson T: The disorders in patients with alcohol and otherdrug problems. Archives of General Psychiatry 45:1023-1031, 1988 HalikaSJA, Herzog MA, Mirassou MM, et al: Psychiatric diagnosis among female alcoholics. Currents in Alcoholism 8: 283-291, 1981 17. Hesselbrock MN, Meyer RE, KeenerJJ: Psychopharmacology in hospitalized alcoholics. Archives ofGeneral Psychiatry 42:1050-1055, 1985 18. HelzerJC, Pryzbeck TR: The co-occurofalcobolism with other psychiatnc disorders in the general population and its impact on treatment. Journal of Studies on Alcohol 49:2 19-226, 1988 rence 1990 4. Survey ofMedical System Users. Washington, DC, Office ofthe Deputy Assistant Secretary for Planning and Management Analysis, Department of Veterans 7. Care: prevalenceofpsychiatric and byMillerNS. 1991 of patients. Alcoholism Screening Procedures Should Be Improved. Washington, DC, General Accounting Office, 1991 15. VA Health and treatment hospitalized 1989 JAMA261:403-407, 16. 1 . Blume in 13. Acknowledgment This detection, R: Health for VA Substance and Utilization PaloAlto,Calif, ofVeterans Diagnostic B, Swindle Affairs, and Depart- 1991 and Statistical Manual of MentalDisorders, 3rd ed, rev. Washington, DC, American Psychiatric Associa- tion,1987 9. International Classification of Diseases, 9th rev, 4th ed. Los Angeles, Practice Management Information Corp, 1992 10. Moos RH, Swindle R, Pasch B: Health Services Utilization for VA Substance Abuse Patients: Utilization and Costs for Fiscal Year 1989. Palo Alto, Calif, Department ofVeterans Affairs, 1991 11. Moos RH,MertensJR,BrennanPL:Patterns ofdiagnosis and treatment among late-middle-aged and older substance abuse patients.Journal ofStudies on Alcobol 17:479-487, 1993 12. Moore VoL 46 RD, Bone No.9 LR, Geller Reviewers Needed Psychiatric Services seeks expert reviewers in the following areas: . Outcome research, particularly in the area of psychopharmacological treatment ofmental disorders I Rating scales for symptoms, outcome, and other aspects of treatment . Dual diagnosis (mental illness and drug abuse and mental illness and mental retardation) . Rural psychiatric services . Patient and consumer perspectives and attitudes Psychiatric Services uses reviewers from all mental health and related disciplines. Reviewers should be familiar with the literature in their aeas of expertise, should have published in peer-reviewed journals, and should be familiar with the content and focus ofPsychiatric Services. Prospective reviewers should send a curriculum vitae, specifying areas ofinterest, toJohn A. Talbont, M.D., Editor, Psychiatric Services, American Psychiatric Association, 1400 K Street, N.W., Washington, D.C. 20005. G, en al: 937 becomes wider. It also allows time for the unhurried exchange of infonmation between staffand patients about the transition from hospital to community, housing for visits to different and discussion with types of former patients who have already made the transition, and for familiarization with the localities eventually chosen. In addition, the houses facilitate the development of social networks that can be maintained after discharge. This feature is particularly important, because mutually suppontive relationships are essential if former patients arc not to become socially isolated (3). A wide range of housing formats in the community is necessary to caten to the needs and choices of prepanation-house residents when they move on. An important pant of this range consists of housing projects specifically designed to provide mdividual apartments for privacy combined with communal areas that allow social contacts and staff support when required (2). Eighty former patients arc now accommodated in five schemes of this type, and their quality of life and satisfaction levels arc very high. We have found this approach invaluable in resolving the dichotomy between patients’ needs for autonomy and fonstructured environments with support that Minsky and associates see as the basis of patient-staff differences in housing preferences. DAVID ABRAHAMSON, F.R.C.PSYCH., F.R.C.P.I. Dr. Abrahamson is a consultant psychiatrist with Redbridge Health Care (Goodmayes Hospital) and Newham Mental Health Rehabilitation Team in Essex and London, England. References 1 . Minsky of the 5, Reisser beholder: inpatients and chiatric Services 2. Abrahamson tionalization, GG, Duffy M: The eye housing preferences of their treatment teams. 46:173-176, 1995 Psy- D: Housing and deinstituin Dimensions of Commu- Mental Health Care. Edited by Wel1cr MPI, Muijen M. London, Saunders, nity 1993 3. Meltzer E, Kemp P, Smith B: Social networks in a cluster ofthree group homes for the mentally ill.Journal ofMental Health 3:263-270, 1994 952 Attachments to the Hospital been total care may be indicated. The and confusion of community life may exacerbate inner disonganization. Patients may experience loneliness, feelings of vulnerability, and homesickness for the friends left behind in the state hospital. They may meet new people in outpatient programs, but, as we all have expenienced, new acquaintances are no substitute for old friends. The measures that Dr. Swett suggested arc an excellent way to identify patients at risk for readmission within 30 days. A first step toward avoiding neadmission may be to interview these patients individually and ask them specifically what they need to live in the community. I am not sure what the answers are. Providing good community care is a complex and difficult task. ELIZABETH W. FARRELL, M.S.W., L.I.C.S.W. noise To the Editor: In the article entitled “Symptom Severity and Number of Previous Psychiatric Admissions as Predictors of Readmission” in the May 1995 issue, Dr. Swett (1) suggested that symptom acuity (as measured by scores on the thought disorden factor and the self-neglect qucstion of the Brief Psychiatric Rating Scale) and a large number of previous admissions can be useful predictors of readmission to the state hospital within 30 days. I would like to add some other points to Dr. Swett’s discussion of symptom acuity among patients who arc at high risk for readmission. Because of their many previous admissions, these patients have developed attachments to hospital staff. In our state hospital, patients who are readmitted within 30 days arc returned to the same unit to ensure continuity of treatment. Persons with schizophnenia cannot be expected to attach readily to new support persons. Such patients have had little opportunity to form attachments in the community. Most have a limited range of adaptive responses, which makes adjustment to new environments difficult. When patients have a great deal ofthought disturbance or inner disorganization, they need the structune that a hospital provides. From their point of view, perhaps their return to the hospital indicates that they know what they need. They need help with self-cane. When one’s thoughts interfere with one’s ability to organize activities, what a reliefto have clean sheets, clothes, and meals provided! In the community, a patient with acute symptoms may have trouble crossing the street to get to a grocery store, let alone marshalling the skills involved in using a laundromat. Because poor self-cane and thought disturbance combine to make a person look different, others arc likely to view him or hen as a “weirdo.” Providers of outpatient care may need to attend to the difficulties many ofthcsc patients have in establishing bonds with new caretakers; a more gradual reduction in what has Psychiatric Services Ms. Farrell is assistant professor in the department ofbehavioralhealth and psychiatry at West Virginia University School of Medicine. She urk at the William R. Sharp, Jr., Hospital in Weston, West Virginia. Reference 1 . Swert ofprevious dictors vices C: Symptom psychiatric severity and admissions of readrrnssion. 46:482-485, 1995 First-Person Sought Psychiatric number as pre- Ser- Accounts for Column Psychiatric Services is seeking firstperson accounts of experiences with mental illness and treatment for the Personal Accounts column, which is now published every other month. Submissions, which should not cxceed 1 ,600 words, should be sent to the column editor, Jeffrey L. Gellen, M.D., M.P.H., Department of Psychiatny, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655. September 1995 VoL 46 No.9 Attend the Your Chance. Couldn’t Here’s Live Audiotapes 1995 Meeting? .On Audiotape . of the Proceedings Annual Available Q4BOC ADVANCES a IN kESEAICE Al R..tdi (os Iwo tapis) PsycIstiy: An Upd.te #{149} SILOS Advances i tot lbs tIIIdaI DATE 0 SL #{149} Di ReioIv Sezi*l Orios B#{225}cIogicsIPbmomeixn LECTUM 0 Li 0 U 0 U 0 LA 0 0 1.6 a L7 0 La 0 L9 D 110 0 Lii 0 L12 0 L13 L14 0 LiS 0 Role L19 0 1.20 0 a 112 a MU2 0 MU3 0 MU4 PAPER 0 0 P2 P3 0 P4 0 P5 D 0 0 P6 0 0 0 0 P9 0 0 0 0 0 P1 Ps PtO P12 P13 P14 P15 P16 P17 P1* P22 P23 P24 P25 0 0 52 S3 a s 0 55 0 56 0 57 0 58 0 59 0 510 0 0 512 0 513 0 514 0 0 SiS 516 517 0 0 519 520 521 0 522 0 523 524 525 526 S27 0 0 0 0 0 SESSIONS #{149} SiS Each Mood tUrorder Comorbidity Predictoti of Aggres.ion and Stacide Trauma in Caildren: Wat, Kitktapping and a Hisricsne Preseatation and Managemnrue of Depresnion: ahitic lanuas Subatmios Aba..: Diagnosis and Trastuneat Psychopathology Prllowing Stroke I.. Coatrol tUwtmeces is Adole.ceats naid Young Adele. MedicatiOn Treatmnis of Deptendon MW Lass.. tiId and Adoleaceis Psychiatry CCtUa.O(MOOd 511 0 UPDATES #{149} SPAS Each Suddai IMaat Death Syndrome Reconatiuctive Facial Surgery for Congeolial and AcqI#{220}OdDeformuti.. onic liver tUsasni for the Practicing Paychistriat Advancea Ia Innaging Techitiques MEDICAL 0 MUI P21 SYMISIA D Si RoiiaSd it. Sbikw. M.D.: Esnme so Pratsice Medicine A Quion 01 Impairmeat, Not Meatal tUna.. Cad. J. Shar,. PkD.: Esain Wava. and Brn Wiring *iiliam H. Ares M.D.: Cognirive D7thniction in Adoleacerts with Conduct Th*wt*nc Iicationa Cot Treatmas akash N. Desa.. M.D.: Tahing the Psyche cam of Psychiatry: The Cane 01 Hindu Medicine Iii Diagno.is RESEARCH two tapes) 0 RAI Teacher a P20 SESSIONS Mosdeoring AND by: Mobiltape MAIL tUflRE in the NOnpaychiatric Populations MediCation Imues Faculty and Residents Working Togather in Stressful Times Biopaychoaodal Issues In OBIOYN Psychotic Disorders Personalky Disorders 0 S2a 0 S30 0 531 0 532 0 S33 S34 0 0 0 535 536 D 0 537 S38 0 539 0 540 0 541 0 542 Disorders Dissociative and Psychotic Disorders Severe Stress and Psychopathology Mature Life Psychiatric lasuas Qiemical Dependency Issues in Psychiatry c1d and Adolasces Psychopathology ADVANCES Research IN MEDICINE Advances #{149} $16.00 (on in Medicine (on tmo tapes) Psychopathology and Psychotherapy of Affective Disorders Psychopharmacology of Worn.. Odiure, Bhnicisy ..sd Rsc Psychiatry. current Uerege Humcsae Andrew: Psychiatric, Immune H..kh Inipacs. Algorithms for Phwnmcothesapy of Schiso Carters Concept.: New Perives on Doprasstr* and Dementia Menial Retardation: Psychiatric Service Models International Guidelines for Diagnoatic #{149} SlOO 0 543 0 544 0 546 0 547 0 54* 0 0 0 549 550 S52 0 553 0 #{149} 534 0 SS5 0 556 0 557 558 0 cOMPANY. Av.nu. Stanford, INC. Suit. 0 559 0 Set 0 562 Why is Depression More Common in Women Than Men? Psychotherapy Practice and Education in a Mana#{231}ndCare Sattin Psychiatrmnis and Their Patients: APAs National Psychiatric Research Natwork Findings Ta.smeat of Complex Medical.Psychiatric Syndromes Ponipastum Psychiatric Disordeor Theories and Treatment Modem Day Bipolar Disorders: Course and 0 563 0 564 0 565 0 566 0 D 567 568 569 0 S 0 0 571 573 0 0 575 576 0 577 0 57$ 0 Antisocial Personality Disorder Spectrum Gender Issues in Scl#{252}ophaenia Intervention for aiikken Exposed to Violator and War Deciolon-Making in Psycho.Oncology Mana#{231}emets of Schtiatplwesic Cnmorbidides Deciiion.Making Coiquntatce: civil and The Onionic Mentally Ill: Do We Have Any Soltsiona? Placebo Response in Psychiatric lilneni Alcoholisuc From Vulnerability to Treatment Biology and Trrsrmeat of Anixenia Nerves. Povetty, ama and Mental Illness Developmental Neurobiology and Psydiotharmacology of PTSD Neurobiology, Psychoanalysis and Asia II: A New Frontier Assessm of PT5I The Uae of Psychophysiology Issues Specific to Depression in Older Women New and Effective Treatments for Substance Abuse New Inseglss in Body Dysmorphic Disorder Brain Structure and Function in the Schiw Spactrea Disease Progression and Emstion A Vision 01 the Potw Patting she Puzzle Together Peinnary Care. Psychiatry and Maanged Care Psychiatry and Heakh in Low Income Ceuntries The Fisure of Cultucal Psychiatry: Service or Training? Depressive Sutaype Tresiment and Diagnostic In#{231}licasions The Mi.mu Mosaic: Mental Health in a Muhticuktunl City What Changes in long-Term Dynamic Tratinsent? 0 5*0 0 0 581 S$3 0 584 0 585 0 586 517 0 0 0 ADDat Wide UmiwelIa Asa..snum and Treatment Diversity in Psychiatric Practice in the Americas The Comprehensive Tr..tment of Substance Abusers Personality Disorders and Substance Abuse Psychiatric Mana#{231}ement Oiildren Who W*nasa Violence by Their Parents Relationship of Personality Disorders to Anxiety and Depression MedicatiOn Backup: lane.. for the PractitiOner Allies and Adveranriex The Impact of Managed Care Psychosocial Btecsa of Genetic Teasing Melatonin in Psychiatric and N.oplastic Disorders Understanding Diversity in Minority Lesbians and Gays Mental Illness and the Arab Cukiate: amend 588 5*9 0 590 0 591 0 592 0 0 593 0 0 595 5% 0 0 597 0 5100 0 5101 994 S95 0 Sh02 0 5103 5104 Work and Psychiatric Disability in Schizophrenia The Diverse Faces 01 Depression gfeceive Aid to Psychiatrists in the Former Eastern European Block The Cuban-American Experience: Mental H..kh Perspectives Contemporary Approaches to Quality Improvement Panic Disorder Uphee Nature and Treatments Gender Issues in Depression Neuroleptic Noncompliance amend Considerations of Reposted Abuse in BPD Cognitive Versus Plnirm.COIOgic*I Factors in Laboratory Models of Panic Schizophrenia: New Approaches Using Old Tr..tments New Concepts in the Neuropsychiatry of Motivation Neurological Models of Psychiatric lliamees Violence Preventioec Toward a Public Health Psy OtD.SpecBem Disorders in a Medical Setting Convening to Managed Care in the Puldic Sector Combination Pharnacothetapy Strategies Early Course and Treatment of Psychotic Disorders Possession-Trance Disordes A New Entity in DSM-IV Eye Movement Desensitization and Rqwocemag: Evidence Pro and Con Neural Circuits in Conical Psychiatry Innovative Treatments of Distress is 1EV CuhureBound Syndromes California 91355 California Ordem 8.25% Sales 1.800.389.5718 Delivery 1tTAL #{149}Ma.terCard aVISA sAmaritan Expr.ss ePersonal Check. (mad. payable to Mobiltape Company. S_________ Tax: S__________ for Taps.: Amount 70, Vaioncia, Inc. School-Aged CalIdren of Drug Abusers: New Rea..rch BPDinMales Diversity and Equality of Gay and Leabian Adolescents Intericisl Psychiatric Disordea New Perspectives Psychiatry Education and the Generalist Initiative Predicton 01 Resposse in Mood Disorders Controversies in Managed Care Sociological Perspectives on Psychiatric Societies Parity and Diversity in France Competence and Mental lIla...: Jewish Soucces Psychiatric Altempis to Onange Sexual Orientation Homelmeners: Psychiatric and Culternl Dimensions Diverse People, Diverse Places Selective Senitosan Reupiake hsthibiiors Response Acsosa the Depressive Spectrum Tr..sment of Agitation in tUderly Patients with Dementia DSM4V t:ultusul Pornaslation and Bhnic Diversity Stages of she Neurobiological Response to Trauma Psychiatric Management in Neurological and 0 MOBILTAPE 25l1 West Company, AD of Psychotropic PRESIDgy’TIAL SYMPOSIUM #{149} SU.OO (oa two tapes) 0 PSi Workiorce Reform and the Fesese of Psychiatry antis M. Mtraclsas, M.D.: Lssrolng to Breaths Undewatat Ekecaelng Psychiatric Lsadnrs for the 21* Ceatury William #{163} Dsw Jr.. M.D.: Rateat Diacovetian in SChi*,phrenia NdsC)#{149}I Weak,. Ph.D.: When Behavior Mirrors DNA: Huisingions Disease As a L17 0 0 0 Recorded and Reunion 0 Neurobiologic 1eatmeat 0 0 Escaping the Cyde 01 Work and Jane Jackson Ch.dasas M.D.: Can Psychiauy Serve Tomorrows Black Ronaliss M5175r51 5. L#{226}vingso.se.P&D.: PId Pioc 01 For Color, Motion and Depik Aioiny, Phyiology, Au and lUanson Jondan J. Cob,, M.D.: Convoioa L2we Donna M. Natri4 M.D.: ldran As ad is Qiody BsUueE ia#{231}licMioaa for the Ptsolng Ps Carolyn #{163} Roiaondtz M.D.: Psychiatric Education and the Fiance 01 Psychiatry John M. MacGregor. PkD.: Henry Dargat Ia the Ranims of the Unreal Ri.ben D. Rambmas. M.D.: iberoamnaican Coatribimion to the Hiato,y ci Psychiatq Lesion I. Hawns M.D.: What Ii Psychiatry AU Abets? Glen 0. GabMrgt M.D.: Oiood Traunna and Psychodyannc Psychiatry: A Timely i5 APPROPRIATE P19 0 Faa #{149} Shipment! 0 is PrinIy. Micka.i L PerTh,. iD.: Myths, kcsIiii the Political Wodd: The Ant&opoiogy In.aay Li. M. FIy.* MA.: The Ccsuma as Ma.pd Health cats kM.: H. Skate, M.D.: Psciy M a Ooroad: Ow Role in Pnuy Cats .i#{252}.i& Schor. Ph.D.: Tame, Wotk and Cassettes. for Immediate Costs: of OsSor S_____________ S__________ lot.) Nams: Strait ( City St*t. Credit Credit Delivery Card Costar Domoatici Overais..: Caok ZIP Expiration ____________________ Number. _____________________ Date: Signaturer. per tape; per taps; 55.00 $5.00 mnxirrsim per order. $20.00 maximum par order. High Quality! Ioo. Number ______________________ ___________________________________ tstequired 52A10 $1.50 ) Cod. Atratralla, par order. #{149} Fast [or mailin Japan, Service! credit MalaysIa, casE South orders) Afrlca 51.50 per tape; $5.00 mininsam I fr Low Delivery FM APA Members Get AllThree FromPennyWiseOfficeProducts... Penny Wise offers 18,000 brand name office supply and furniture items at guaranteed lowest prices - from 20% to 85% off retail! Plus, members save even more: . Members automatically . Guaranteed S FREE, fast delivery in the continental U.S. ($25 minimum order) S a save up to an additional 11% lowest price Toll-free ordering by phone, fax or modem FREE, no-hassle retum policy Call toll free now for your FREE full color catalog. ..ask for our FREE PC software for computer ordering. 1(800)9l-3311 (301) 699-1000 ‘CE pgO F.- in the Washington, DC area
© Copyright 2024